[House Hearing, 113 Congress] [From the U.S. Government Publishing Office] AGRICULTURE, RURAL DEVELOPMENT, FOOD AND DRUG ADMINISTRATION, AND RELATED AGENCIES APPROPRIATIONS FOR 2014 _______________________________________________________________________ HEARINGS BEFORE A SUBCOMMITTEE OF THE COMMITTEE ON APPROPRIATIONS HOUSE OF REPRESENTATIVES ONE HUNDRED THIRTEENTH CONGRESS FIRST SESSION ________ SUBCOMMITTEE ON AGRICULTURE, RURAL DEVELOPMENT, FOOD AND DRUG ADMINISTRATION, AND RELATED AGENCIES ROBERT B. ADERHOLT, Alabama, Chairman TOM LATHAM, Iowa ALAN NUNNELEE, Mississippi KEVIN YODER, Kansas JEFF FORTENBERRY, Nebraska THOMAS J. ROONEY, Florida DAVID G. VALADAO, California SAM FARR, California ROSA L. DeLAURO, Connecticut SANFORD D. BISHOP, Jr., Georgia CHELLIE PINGREE, Maine NOTE: Under Committee Rules, Mr. Rogers, as Chairman of the Full Committee, and Mrs. Lowey, as Ranking Minority Member of the Full Committee, are authorized to sit as Members of all Subcommittees. Martin Delgado, Tom O'Brien, Betsy Bina, Pam Miller, and Andrew Cooper, Staff Assistants ________ PART 5 Page USDA Farm and Foreign Agricultural Services...................... 1 Food and Drug Administration..................................... 177 S ________ Printed for the use of the Committee on Appropriations PART 5--AGRICULTURE, RURAL DEVELOPMENT, FOOD AND DRUG ADMINISTRATION, AND RELATED AGENCIES APPROPRIATIONS FOR 2014 ? AGRICULTURE, RURAL DEVELOPMENT, FOOD AND DRUG ADMINISTRATION, AND RELATED AGENCIES APPROPRIATIONS FOR 2014 _______________________________________________________________________ HEARINGS BEFORE A SUBCOMMITTEE OF THE COMMITTEE ON APPROPRIATIONS HOUSE OF REPRESENTATIVES ONE HUNDRED THIRTEENTH CONGRESS FIRST SESSION ________ SUBCOMMITTEE ON AGRICULTURE, RURAL DEVELOPMENT, FOOD AND DRUG ADMINISTRATION, AND RELATED AGENCIES ROBERT B. ADERHOLT, Alabama, Chairman TOM LATHAM, Iowa ALAN NUNNELEE, Mississippi KEVIN YODER, Kansas JEFF FORTENBERRY, Nebraska THOMAS J. ROONEY, Florida DAVID G. VALADAO, California SAM FARR, California ROSA L. DeLAURO, Connecticut SANFORD D. BISHOP, Jr., Georgia CHELLIE PINGREE, Maine NOTE: Under Committee Rules, Mr. Rogers, as Chairman of the Full Committee, and Mrs. Lowey, as Ranking Minority Member of the Full Committee, are authorized to sit as Members of all Subcommittees. Martin Delgado, Tom O'Brien, Betsy Bina, Pam Miller, and Andrew Cooper, Staff Assistants ________ PART 5 Page USDA Farm and Foreign Agricultural Services...................... 1 Food and Drug Administration..................................... 177 S ________ Printed for the use of the Committee on Appropriations U.S. GOVERNMENT PRINTING OFFICE 82-639 WASHINGTON : 2013 COMMITTEE ON APPROPRIATIONS HAROLD ROGERS, Kentucky, Chairman C. W. BILL YOUNG, Florida \1\ NITA M. LOWEY, New York FRANK R. WOLF, Virginia MARCY KAPTUR, Ohio JACK KINGSTON, Georgia PETER J. VISCLOSKY, Indiana RODNEY P. FRELINGHUYSEN, New JerseyJOSE E. SERRANO, New York TOM LATHAM, Iowa ROSA L. DeLAURO, Connecticut ROBERT B. ADERHOLT, Alabama JAMES P. MORAN, Virginia KAY GRANGER, Texas ED PASTOR, Arizona MICHAEL K. SIMPSON, Idaho DAVID E. PRICE, North Carolina JOHN ABNEY CULBERSON, Texas LUCILLE ROYBAL-ALLARD, California ANDER CRENSHAW, Florida SAM FARR, California JOHN R. CARTER, Texas CHAKA FATTAH, Pennsylvania RODNEY ALEXANDER, Louisiana SANFORD D. BISHOP, Jr., Georgia KEN CALVERT, California BARBARA LEE, California JO BONNER, Alabama ADAM B. SCHIFF, California TOM COLE, Oklahoma MICHAEL M. HONDA, California MARIO DIAZ-BALART, Florida BETTY McCOLLUM, Minnesota CHARLES W. DENT, Pennsylvania TIM RYAN, Ohio TOM GRAVES, Georgia DEBBIE WASSERMAN SCHULTZ, Florida KEVIN YODER, Kansas HENRY CUELLAR, Texas STEVE WOMACK, Arkansas CHELLIE PINGREE, Maine ALAN NUNNELEE, Mississippi MIKE QUIGLEY, Illinois JEFF FORTENBERRY, Nebraska WILLIAM L. OWENS, New York THOMAS J. ROONEY, Florida CHARLES J. FLEISCHMANN, Tennessee JAIME HERRERA BEUTLER, Washington DAVID P. JOYCE, Ohio DAVID G. VALADAO, California ANDY HARRIS, Maryland ---------- 1}}Chairman Emeritus William E. Smith, Clerk and Staff Director (ii) AGRICULTURAL, RURAL DEVELOPMENT, FOOD AND DRUG ADMINISTRATION, AND RELATED AGENCIES APPROPRIATIONS FOR 2014 ---------- Thursday, April 25, 2013. U.S. DEPARTMENT OF AGRICULTURE FARM AND FOREIGN AGRICULTURAL SERVICES WITNESSES MICHAEL SCUSE, UNDER SECRETARY, FARM AND FOREIGN AGRICULTURAL SERVICES JUAN GARCIA, ADMINISTRATOR, FARM SERVICE AGENCY SUZANNE HEINEN, ADMINISTRATOR, FOREIGN AGRICULTURAL SERVICE BRANDON WILLIS, ADMINISTRATOR, RISK MANAGEMENT AGENCY MICHAEL YOUNG, BUDGET OFFICER, DEPARTMENT OF AGRICULTURE Introduction of Witnesses Mr. Aderholt. Good morning. Our subcommittee will come to order. We appreciate everyone being here this morning for your testimony before the Subcommittee. We will begin our review of the fiscal year 2014 budget request from the agencies of USDA's Farm and Foreign Agricultural mission area. While the FDA appropriation hearing is tomorrow and it will be our last regularly scheduled appropriation hearing, today is our last of nine USDA budget hearings for fiscal year 2014. I want to welcome Mr. Michael Scuse, USDA Under Secretary for Farm and Foreign Agricultural Services; Mr. Juan Garcia, Administrator, Farm Service Agency; Ms. Suzanne Heinen, Administrator, Foreign Agricultural Service; Mr. Brandon Willis, Administrator, Risk Management Agency; and last but not least, Mr. Mike Young, USDA's Budget Director. Opening Statement Many of our fellow Americans do not see the behind the scenes of this mission area, though the vital programs managed by these agencies help farmers, ranchers and growers produce an abundant supply of diverse foods for the United States and people around the globe. From the farm operating loans for beginning farmers to crop insurance needed to manage financial risk to the agricultural attache in foreign countries fighting for the U.S. market share, we expect this mission area to provide many services that are critical to the backbone of our agricultural economy. The ongoing challenge for this Subcommittee is to provide limited resources to the highest priority needs of agriculture and often times the priority with the greatest return on investment. As your testimony points out, this mission area has made a number of positive steps to control costs, one being the closing of 125 field offices and two overseas offices, condensing the number of reporting dates for reporting acreage and crop data, and reducing staffing levels by using existing authorities. You also have a positive story to tell on trade. That being said, there is always room for improvement in the way USDA manages the American taxpayer dollar. The fiscal year 2014 President's budget for Farm and Foreign Agricultural Services mission area seeks total discretionary funding of $2.032 billion, of which approximately $1.59 billion is for the Farm Service Agency programs, and $373.3 million is for the Foreign Agricultural Service programs. While there are smaller increases and decreases, the one major change is on the discretionary side, a proposal to fundamentally change the nearly 60 year old Food for Peace program in this appropriation by transferring nearly $1.4 billion to USAID. Additionally, with just a two percent increase in loan support, the request estimates a 22 percent increase in loan authorizations for farm ownership and operating loans. This backing will help an additional 34,000 farmers and ranchers. We look forward to getting answers to a number of questions that we have on the President's request. Before I recognize you, Mr. Scuse, for your opening statement, I would like to ask the Ranking Member of the Subcommittee, the gentleman from California, for any opening comments he may have. Mr. Farr. Mr. Chairman, I always look forward to these hearings. We have essentially people who administer the ground level in America, the most basic production of the lands that produce our agriculture and carrying that agriculture all the way to its furthest point on earth, in all the countries we have international relations and offices with, so we really can market our products abroad. A lot of my questions are going to be about how you use your authorities. I have been on this Committee a long time. Every year we go through this. What I think the Federal Government and Secretary Vilsack is keen on is trying to build the capacities by building sort of local capacity. I want to focus on some of those issues, about how to use your authorities as a carrot stick to kind of encourage local capacity building, whether it be the local level or the foreign level. I appreciate you coming today and I appreciate your testimony. Thank you, Mr. Chairman. Mr. Aderholt. Thank you, Mr. Farr. If anybody has any electronic devices, if they could put those on mute during the hearing. Also, let me just say not only to you, Under Secretary Scuse, but also to all our panel, members are going to be coming and going because we have 12 appropriation bills that we are working on simultaneously. Inevitably, there are going to be hearings that take place at the same time, so if members come in and out, it is nothing you said. It is just part of the process. Please understand that. Without objection, your entire written testimony will be included in the record. I will now recognize you, Mr. Under Secretary, for your opening comments, and then we will proceed with the questioning. Opening Statement Mr. Scuse. Mr. Chairman, Ranking Member, I would like to thank both of you for your opening comments this morning. It is refreshing that we have those that understand what the Farm and Foreign Agricultural Service does and the importance that it plays in the lives of Americans. I would like to thank all the members of the Subcommittee for being here today, and I am pleased to be with you today to present the 2014 budget and program proposals for the Farm and Foreign Agricultural Services. As you pointed out, Mr. Chairman, accompanying me today is Brandon Willis, Administrator of the Risk Management Agency; Suzanne Heinen, Administrator of the Foreign Agricultural Service; Juan Garcia, Administrator of the Farm Service Agency. Also with me today is Michael Young, Director of the Department's Office of Budget and Program Analysis. Mr. Chairman, we appreciate the difficulties of today's budget environment and the need to reduce the Federal deficit. We have reviewed our programs and developed proposals that will streamline our operations, improve efficiency, and reduce our administrative costs. Turning to the Farm Service Agency, the budget request for salaries and expenses of FSA is $1.6 billion, which is a decrease of $179 million since 2012. The request reflects our focus on streamlining processes, investing in more efficient systems, and evaluating our internal costs to maximize efficiency. FSA provides a broad range of services for American agriculture, disaster assistance, income support payments, marketing assistance loans, and certain conservation programs. FSA also plays a critical role in our nation's agricultural production by providing a variety of direct loans and loan guarantees to farm families who are temporarily unable to obtain the credit they need. For the Farm Credit Program, the budget proposes a program level of about $5.6 billion, an increase of about $1 billion from 2012, at a subsidy cost that is about $16 million less. The request reflects the ongoing credit needs of beginning and minority farmers. For the 2012 crop year, the Risk Management Agency through the Federal Crop Insurance Program provided a record $117 billion in protection, which is on a record 282 million acres of farm land. Due to the widespread drought and other natural disasters that impacted agricultural producers during the crop year, the program has paid out more than $16 billion in indemnities to producers, which is also a record. Our current projections for the 2013 crop year are liabilities will decline to about $82 billion, largely the result of lower commodity price projections. For the salaries and expenses of RMA, the budget requests $71 million to support 455 employees, compared to 2010's $80 million appropriation that supported 528 employees. It is a reduction of about 11 percent and 14 percent, respectively. The Foreign Agricultural Service leads the Department's efforts to expand and preserve overseas markets and foster global food security. The budget is designed to ensure that FAS has the resources needed to represent American agriculture and create new market opportunities overseas. The budget provides $179 million for FAS salaries and expenses, about $7 million below 2011. For trade expansion and promotion activities, the budget does include $200 million for the market access program. Other trade promotion activities such as foreign market development are subject to re-authorization and their appropriation levels will be set in the next Farm Bill. For International Food Aid, the budget includes $185 million for McGovern-Dole and $255 million for Food for Progress. For P.L. 480, Title II, the budget provides $1.47 billion in the accounts of USAID rather than USDA, consistent with the Administration's food aid reform proposals. I would like this morning to make two announcements, two very important announcements, working with OMB, we have received our Section 714 funding, and we will not be furloughing any of the staff for the Farm Service Agency. The second announcement is that we have been working for several years on our modernization project for our Farm Service Agency County Offices. I would like to announce before this Committee today that program is live nationwide. We now have this morning 3,300 users using the MIDAS Program. By the end of the day, there will be another 2,200 added for a total of 5,500 users nationwide using our modernization program, and within the next 30 days, we fully expect to have everyone across the United States fully trained and tested to use that program. I want to thank this body and Members of Congress for their support, financial and otherwise, in helping us reach this major milestone on a project that was desperately needed to help our County Office staff, and get rid of a system that was antiquated, to say the very least. Again, thank you. [The information follows:] [GRAPHIC] [TIFF OMITTED] T2639A.001 [GRAPHIC] [TIFF OMITTED] T2639A.002 [GRAPHIC] [TIFF OMITTED] T2639A.003 [GRAPHIC] [TIFF OMITTED] T2639A.004 [GRAPHIC] [TIFF OMITTED] T2639A.005 [GRAPHIC] [TIFF OMITTED] T2639A.006 [GRAPHIC] [TIFF OMITTED] T2639A.007 [GRAPHIC] [TIFF OMITTED] T2639A.008 [GRAPHIC] [TIFF OMITTED] T2639A.009 [GRAPHIC] [TIFF OMITTED] T2639A.010 [GRAPHIC] [TIFF OMITTED] T2639A.011 [GRAPHIC] [TIFF OMITTED] T2639A.012 [GRAPHIC] [TIFF OMITTED] T2639A.013 [GRAPHIC] [TIFF OMITTED] T2639A.014 [GRAPHIC] [TIFF OMITTED] T2639A.015 [GRAPHIC] [TIFF OMITTED] T2639A.016 [GRAPHIC] [TIFF OMITTED] T2639A.017 [GRAPHIC] [TIFF OMITTED] T2639A.018 [GRAPHIC] [TIFF OMITTED] T2639A.019 [GRAPHIC] [TIFF OMITTED] T2639A.020 [GRAPHIC] [TIFF OMITTED] T2639A.021 [GRAPHIC] [TIFF OMITTED] T2639A.022 [GRAPHIC] [TIFF OMITTED] T2639A.023 [GRAPHIC] [TIFF OMITTED] T2639A.024 [GRAPHIC] [TIFF OMITTED] T2639A.025 [GRAPHIC] [TIFF OMITTED] T2639A.026 [GRAPHIC] [TIFF OMITTED] T2639A.027 [GRAPHIC] [TIFF OMITTED] T2639A.028 [GRAPHIC] [TIFF OMITTED] T2639A.029 [GRAPHIC] [TIFF OMITTED] T2639A.030 [GRAPHIC] [TIFF OMITTED] T2639A.031 [GRAPHIC] [TIFF OMITTED] T2639A.032 [GRAPHIC] [TIFF OMITTED] T2639A.033 [GRAPHIC] [TIFF OMITTED] T2639A.034 [GRAPHIC] [TIFF OMITTED] T2639A.035 [GRAPHIC] [TIFF OMITTED] T2639A.036 [GRAPHIC] [TIFF OMITTED] T2639A.037 INTERNATIONAL FOOD AID REFORM Mr. Aderholt. Thank you, Mr. Under Secretary, and for those announcements, we appreciate your testimony here this morning and for your work at your agency and what you do. Let me go ahead and start with the questioning aspect for the hearing today. One thing that most people with agriculture have noted is the Obama Administration is proposing to transfer funding for the Public Law 480, Title II, Food for Peace Program in the agricultural appropriations and move it into the state and foreign operations appropriations under three separate accounts at USAID. We are still looking at these changes here at the Subcommittee level and at the full Committee level of what it would mean. We do need to keep in mind that the unemployment rate is 7.6 percent, and 11.7 million people are without jobs. The President's proposal would reduce the amount of food provided and shipped by American farmers and ranchers to those in need around the globe, from the current level of approximately 80 percent of $1.12 billion to roughly 55 percent or $605 million. As noted in your testimony, USDA's Economic Research Service estimates that for every billion of agricultural exports, an estimated 6,800 jobs are supported, and an additional $1.29 billion in economic activity is generated. The way the program is currently structured almost doubles the return on the American taxpayers' investment by supporting jobs and farmers here at home, while still accomplishing the goal of contributing to food security abroad. With budget reductions in all sectors and millions of Americans struggling to find work, is it a wise use of the taxpayer money to maximize our investment at home while also contributing to the needs of those overseas? Mr. Scuse. Thank you, Mr. Chairman, for the question. If you look at just the trade aspect, which you pointed out, we have had the last four years record amounts of trade, and this year, for another record year of $142 billion in agricultural trade. We are doing everything that we can to promote American agricultural products throughout the world. We support the Administration's position on this transfer. If you look at what this will ultimately do, we are still going to be sending 55 percent of the U.S. products overseas for food assistance, we believe through the efficiencies and being able to buy locally products, two things will be accomplished. First, we are going to get aid to an additional two million people a year by making this change. The second thing that comes to mind is we are going to be able to get this emergency food assistance to those that are in need much quicker. If you look at how long it takes us today to get emergency food assistance through our current program to those countries that are truly in need, it is over 70 days. We can decrease that time line substantially by taking some of the funding and buying regionally the products needed in a very short period of time. Mr. Aderholt. How does USDA foresee its role changing in providing the international food assistance given this reform proposal? Mr. Scuse. We are still going to be involved in the procurement of that 55 percent of those products and the shipping from the United States to those countries in need. We are still going to have involvement in this program. FOOD FOR PROGRESS PROGRAM Mr. Aderholt. According to your testimony, USDA would still obligate roughly $255 million out of the Commodity Credit Corporation for the Food for Progress Program. Do you think your Department can continue to effectively and efficiently invest $255 million in the Food for Progress Program on development projects? Mr. Scuse. I believe so. Again, we are still going to be doing the procurement for AID for the 55 percent, and then the procurement for the $255 million for the other program. I think we are going to be able to continue to provide the work at a reasonable rate and still do it efficiently as well. Mr. Aderholt. Why would you not recommend that the Administration simply expand its ongoing program at USDA instead of sending an additional $250 million over to USAID for the same purpose under a new program? Mr. Scuse. I do not know that we can. It may take legislation to make the change. That would be something we would have to look at with AID as well as the General Counsel's Office from AID and USDA. Mr. Aderholt. Mr. Farr. Mr. Farr. Thank you, Mr. Chairman. I think the food we send abroad is probably the most expensive food in the world, giving to people who are the poorest in the world. It seems like there is a better way to do it. The problem is there is a lot of corruption at the local level with distribution of food because you are in a country where we do not control the distribution politics. Even some good organizations, non-profit organizations, have been known to be selling the food. We do not buy it for people to sell it. What I would hope is that USAID could design a better model of implementation of aid to empower these countries--you are not going to just be able to feed Sub-Saharan Africa with the amount of poverty and the amount of migration, displaced folks, just with U.S. food aid. You are going to have to start empowering the rural areas to grow their own agriculture and have their own markets and things like that. It does not seem like that is at all part of this formula. I do not think we ought to just change it for change sake. We ought to get a better bang for our buck. I share your concerns about it. FURLOUGHS I want to ask, you indicated, and it is good news, that you are not going to have to lay off anybody from FSA, but what about RMA and FAS from sequestration? Are there layoff's there? Mr. Scuse. No, sir. We had never planned to have any furloughs with the Foreign Agricultural Service or RMA. CONSERVATION RESERVE PROGRAM Mr. Farr. Let me ask you a question. I was interested in your resume and the fact that you served as Chairman of the Kent County, Delaware Regional Planning Commission. My question goes to the Conservation Reserve Program, which we began in 1985. I come from a state that is very heavily zoned. Every city and county has to have a master plan. The master plan has to address certain elements, housing elements, conservation, hazardous areas and things like that, and then your zoning has to meet your master plan, as you know. Why have we been sort of bailing out these states with CRP when they do not take any initiative to essentially ban farming on areas you should not farm? If we have a riparian area or habitat that needs protecting, regardless of if it is on private land, you cannot go out and destroy it. It seems what we have been doing is paying farmers not to destroy it. Why do we not require--why do we not provide some leadership, as you did when you were a regional planner, of making communities kind of come up to the standards that were set? It does not seem like we have done that in this program. I just wanted your reflection on it. What it seems to me we are doing, and correct me if I am wrong, but CRP assists farm owners to not do bad things. You are essentially saying we will pay you not to do bad things, where best management practice is do not do those anyway. You cannot do them. In some states, you cannot do them. If you had to pay for all the CRP assets that California counties have protected, ag counties, you would take the entire program. We have just done it through our local zoning and enforcement of our zoning practices. We do not pay people to do it correctly. We tell them that is how you are going to have to do it so you will not have soil erosion. Mr. Scuse. Congressman, I appreciate your point. As you are well aware, there are differences among the states. We have some states that have very weak if any zoning regulations at all. It would be very difficult for them to take the appropriate action within their states. Mr. Farr. How much money do those states get? Mr. Scuse. It will vary from state to state, depending on how much CRP is in the states. This money does not go to the state, it actually goes to the land owner who is taking their land out of production. If I may point out, there is a tremendous environmental benefit to what we are---- Mr. Farr. But it is a huge cost that I think is not essentially best management practices. It is like sort of paying people not to have child labor. We do not have child labor because there are laws against it. Mr. Scuse. In some instances, in most instances, in fact, we are protecting environmentally sensitive land, land we have been protecting since the inception of CRP, over eight billion tons of top soil. Mr. Farr. What about the EPA's regulations? What about on the coastal areas, Marine Fisheries or Fish and Wildlife? They have regulations that say you cannot disturb this. Mr. Scuse. In some of those areas, we use the Conservation Reserve Enhancement Program, which is part of CRP, in coordination and cooperation with the states, with state funding, to protect some of those areas that you have just pointed out. Mr. Farr. Could you for the record, in writing, just point out what states or counties you have weaned off the program because they have taken responsibilities to enforce what I call ``best management practices?'' Mr. Scuse. Sure. [The information follows:] [GRAPHIC] [TIFF OMITTED] T2639A.038 [GRAPHIC] [TIFF OMITTED] T2639A.039 [GRAPHIC] [TIFF OMITTED] T2639A.040 Mr. Farr. Thank you. Mr. Aderholt. Mr. Valadao. MIDAS Mr. Valadao. Thank you, Mr. Chair. Mr. Under Secretary, congratulations on the release of MIDAS. I am pretty excited to follow it myself. My question specifically is can you please expand a little bit on how and when farmers will actually have access to it and how they will be able to benefit from it? Mr. Scuse. The farmers will have access to it immediately. We are looking at being able--I say ``immediately.'' We need to get our staff. That is one of the reasons why we started it in phases, to get the staff fully comfortable with the use of it. It will be in the next few weeks. We are going to be using this product with our farms. There are different phases for MIDAS. This is the first phase for our farm records. We will be able to update our producer records when they come into the office. I think the biggest change that farmers and ranchers are going to see is now we do not use two different systems when they come in to do a crop report. We are going to be able now to combine everything into a single system, which will save not just staff time but save reporting time by our farmers and ranchers. We are still using a great deal of paper when a producer comes in to do a crop report. This system will allow us to not have to go actually do paper maps and draw lines on paper, fields or portions of fields. That will all be able to be done on the screen itself. We are excited about this. I think where your question is going is when will farmers actually be able to do this at home, there is another initiative, the Acreage Crop Reporting Streamlining Initiative that we started a year and a half ago, which is one of the reasons why we consolidated all those crop reporting dates down. We are going to do a pilot project with that in the State of Kansas, in four counties, this Spring. Where we hope to go with that is to actually allow the producers to do one stop shopping. As a producer yourself, if you have crop insurance, you now have to give two reports, one to FSA and one to your insurance agent. This will allow a producer to do one and ultimately do a report right from their farm office. ACREAGE CROP REPORTING Mr. Valadao. To follow up on that, there is quite a bit of information when you go down to the Farm Service Agency that they have and ask for. When we wait for NASS reports, it is almost like they are guessing. As much information as your Department has, why do we not go off that instead of NASS? Mr. Scuse. A good point. One of the things that we did when we started to put together the Acreage Crop Reporting Streamlining Initiative, we got multiple agencies into a room. NASS was one of those agencies, and NRCS was one, the Risk Management Agency and the Farm Service Agency that are under me. There were some issues because four different agencies identified the same parcel of land four different ways. It was very difficult to combine the information that you would ask for. What we were able to do was to get the four agencies to agree on one common land identifier. They can still use their own, but for purposes of cross reporting, there will be one common land identifier. This is one of the things that we also pointed out to NASS, to your point, that with the MIDAS system, with the Acreage Crop Reporting Streamlining Initiative, with those two in place, we are going to be able to get data much faster and more accurate to NASS for more accurate crop reporting. Mr. Valadao. Thank you. Mr. Aderholt. Ms. Pingree. CROP INSURANCE FOR ORGANIC FARMERS Ms. Pingree. Thank you, Mr. Chair. Thank you very much for you all being here today and for your previous testimony. Appreciate that. I want to ask a couple of questions about Risk Management. I was encouraged to see RMA's recent announcement on removal of the five percent premium surcharge assessed against all organic farmers seeking Federal crop insurance that starts in crop year 2014. I appreciate this was in response to an earlier release by the Inspector General Audit of Organic Crop Insurance. As you know, the audit found that transitional crop yields for organic farmers using organic crop insurance generally exceeded actual production histories. This arbitrary organic surcharge has been an issue I have heard a lot about in Maine and from farmers across the country. I am very pleased to see this progress. I remain concerned that only about a quarter of organic farmers are enrolled in Federal crop insurance. In addition to eliminating the surcharge, are there other steps that RMA can take to increase organic crop insurance participation? I know it is something that would be of great benefit, particularly with out unpredictable weather patterns. I think more people would like to participate but they are not there yet. Can you talk a little bit about that? Mr. Willis. I share your concern, approximately 25 percent of the acres that could be enrolled in the crop insurance program are enrolled. You talked about eliminating the five percent surcharge. That was the first step. The yield differences you also referred to would be a second step. Another complaint that organic producers often have about the program is they often receive a premium in the marketplace on production, and their crop insurance program, we are slowly trying to get there. Currently, we have eight crops where farmers can elect to receive that organic price. What we are working on is kind of a two pronged approach to increase the number of crops. Last year we funded a NASS survey of organic prices, and we are looking at that survey trying to determine which crops we can expand in the near future. We have a list of those crops. I think in the next month we can announce some for 2014, some additional crops, almonds, apples, blueberries, wheat, and some stone fruits. The other thing we are looking at doing is trying to create a policy where if producers have a contract with somebody to purchase, and there is a price in that contract, see if there is a way there to respect the contract they have within reason so they can also have an organic price. I think our focus now is implementing the changes you discussed and also trying to have more crops receive the organic price. Ms. Pingree. Maybe just to drill down on that a little, it is my understanding it has been six years getting to the few crops that are defined, and I am heartened to hear you are going to add some more. Not fully understanding the process that you go through, what makes it take so long, what is complicated about doing this? Mr. Willis. I think there is a strong desire to make sure we have an accurate price because the last thing anybody wants is for the price to be too high or too low and to somehow drive production. I think that is why a few years ago they contracted with NASS to get more information. We have individuals at RMA that look at all sorts of private sector information, NASS information. It is just trying to get enough price data that we are confident enough we can offer that. It is really just getting confidence in the data. Obviously, the data on organic crops is thinner. Ms. Pingree. It is increasing given the expansion of the market and the more national sales that are going on on a lot of varieties of things that people grow. On this suggestion, which does seem like it would be useful to look at a contract and then maybe use that as a determinant if there was an insurance need, does that happen in other ways? I am not that familiar with how crop insurance works. Mr. Willis. Yes, we have used it for other policies in the past, and we will kind of look at how we did it there, I think, to kind of set the parameters for how we do it in this situation as well. Ms. Pingree. It is within the parameters of appropriate insurance policy? Mr. Willis. Yes, we have done it historically. Ms. Pingree. It would seem to me if that was allowable, then you could greatly expand the number of things you could cover because it does not have to just be corn or almonds or something that has a huge commodity market or big national sales. You could do lots of things that people do get contracts for every year, but we do not always think of it as prime crops. I hope you will keep me updated. I am very interested in this. Thank you, Mr. Chair. Mr. Aderholt. Thank you. Mr. Nunnelee. SEQUESTRATION IMPLEMENTATION Mr. Nunnelee. Thank you, Mr. Chairman. Thank you, Mr. Secretary, for being here. And I want to go back to that very significant announcement you made in your testimony about your agency's ability to avoid furloughs. I want to thank you for the approach that you have taken, certainly my FSA agents in Mississippi and communicating to them, getting us through this, but I am curious about how did you plan for sequestration? How did you get to the point where it was not necessary to have furloughs in order to implement sequestration? Mr. Scuse. Well, we have worked, the three agencies under me, to make cuts and reductions since last fall, not knowing what may happen. And I think that is why when I was asked earlier about the impacts on RMA and the Foreign Agricultural Service, there were no furloughs for those agencies. But just the sheer size of the Farm Service Agency and the offices that we have throughout the 50 states, it was very difficult for them to make the same level of cuts that the other two agencies were to avoid the furloughs. We have the ability to use CCC funding, the Section 714 funding, to cover some of our operational costs. What we were working with OMB on was that we felt that we have not received the cost recovery for our conservation programs that we have been doing. And we are permitted to recoup those costs under the CCC language or under the 714 language. So, we made a request for OMB to allow us to use the 714 language to cover operating costs for our conservation programs and some of the other programs that are under CCC. They have agreed to allow us to do that, but I do not want the committee to believe for one minute that this is just money that fell from the sky because we have to do an offset for that money. And we were able to come up with an offset in order to receive the 714 money. So we just were notified yesterday by OMB that they did agree to allow us to use the 714 to cover our operating expenses for our conservation programs with the offset that we provided. Mr. Nunnelee. I cannot tell you how refreshing it is to hear you make the statement, ``We started planning for sequestration in the fall.'' I cannot express my frustration at the long line of witnesses that we have had in various subcommittees that said, ``Oh, we did not start planning for sequestration until two days before.'' So, thank you for your stewardship of the taxpayer dollars and managing a very difficult situation. CROP INSURANCE Let me move now to implementation of direct payments. I think it is obvious to a lot people that whatever we work out in the farm bill, direct payments are going to be a thing of the past. But when I talk to agri-business owners, when I talk to lenders, they have got to have some kind of certainty in order to make the loans to put the crop in the ground. So, just in general, where do you see us going in order to give farmers and lenders the certainty necessary to plant their crop in light of the fact that we are probably not going to have direct payments in a long-term farm bill? Mr. Scuse. I think that certainty can be provided through a strong safety net. We have a very healthy and strong crop insurance program. I think if you look at the banking industry today, many will require their producers to be covered with some sort of insurance for that certainty. If you look at the programs that I believe are in the President's recommendation, and I think were in the farm bills that the House and the Senate version that did not pass last year, there are the four programs. Three of those programs cover our livestock producers with the LIP, ELAP and LFP programs. So those programs I think will also provide some sort of certainty and insurance that if there are weather-related events, that there will be some sort of compensation. So, I think that certainty, sir, is in the safety net that is provided to our farmers and ranchers. Mr. Nunnelee. What about for those crops for which there is no insurance? Mr. Scuse. Well, we do have the NAP insurance through the Farm Service Agency, and I think that there are proposals or will be proposals in the coming farm bills that will allow us to strengthen that NAP insurance for those products that we do not currently offer crop insurance for. Mr. Nunnelee. Alright, thank you, Mr. Chairman. Mr. Scuse. You are welcome, sir. Mr. Aderholt. Mr. Bishop. MECHANICALLY-SEPARATED POULTRY Mr. Bishop. Thank you very much. Let me welcome all of you this morning. I am going to start off I think with Ms. Heinen. We are aware that the Food Safety and Inspection Service has decided to postpone a sampling of mechanically-separated poultry until it can consider the stakeholder comments on their proposed new rules, specifically, regarding that notice which was entitled, ``The HACCP Plan Reassessment for Not Ready to Eat Comminuted Poultry Products and Related Agency Verification Procedures.'' Has the Foreign Agricultural Service evaluated the economic implications of what might essentially be destroying the export market of mechanically-separated poultry, which has implications for flooding the domestic market and reducing exports? And the second part of that question is did FSIS discuss this with FAS, the international trade implications of the proposed new rules before they published the notice? Ms. Heinen. Well, as you know, Mr. Bishop, the FSIS has the mission to protect the safety of the U.S. public, and so I think they are doing what they feel is necessary to do that. On the export market, one of the things that is our biggest seller overseas is the confidence that our traders or our partners overseas, other countries, have in the safety and the quality of the U.S. product, and the confidence they have in our regulatory agencies. So, if this is the step that FSIS thinks they need to take, we support their efforts to improve the safety of our food. Mr. Bishop. But my question was whether or not they had discussed it with you, have you had any collaboration on it? Did they ask or inquire about what implications there might be? Mr. Scuse. Congressman, I personally have been involved in a discussion that we had with the industry with Under Secretary Hagen within the last month. We did have the conversation. The industry did report their concerns to us. Under Secretary Hagen expressed her concerns with not going forward with this, and the implications that should something happen that they could lose the market. I believe it is a $300 million market for the mechanically-separated poultry. And the fear is that should something happen in a foreign country, that not just a portion of that would be lost but a great deal of that market may be lost. Mr. Bishop. So you have been involved in those discussions? Mr. Scuse. Yes, sir. BRAZILIAN COTTON Mr. Bishop. Thank you very much. Ms. Heinen, as you know, American agriculture has been openly criticized by international operations and eminent academicians for agricultural subsidy, which I call support, and other related programs which support and strengthen our food production capacity here in America. And we are not alone in this arena, as both developed and developing countries are offering their agriculture industries a wide variety of support and protection-like programs. I am concerned about nations like Brazil, which successfully brought the claim against the United States through the WTO on cotton. And also they are providing their key agricultural industries government support on their own in a direct attempt to compete with United States agriculture. As such, our worldwide competitors on a number of levels are doing this, and we need to treat them as such. Where are we with the WTO Brazilian cotton issue? And are there any other similar cases on the horizon, particularly on the part of developing nations that could affect American agriculture? Ms. Heinen. Well, on the first case with Brazil, of course we still need to make changes in the cotton program. Mr. Bishop. Is your microphone on? Ms. Heinen. Is it on? Mr. Bishop. There, that is better. Ms. Heinen. We are still working with you to make appropriate changes so that we can comply. The United States agricultural system is well understood in the WTO, and we are staying within our allowed rights within the WTO. We share your concern that some countries may not be doing this, and we have spent some time this year looking at some other countries and whether or not they are living up to their obligations. We are concerned in the case of Brazil about their premium for product flow--PEP--program, which we think in some cases may have been used inappropriately. So, we are watching this. We are analyzing different approaches countries are taking to ensure that they are living up to their WTO commitments as well. Mr. Bishop. Thank you. My time is up, and I will come back to tomato dumping from Mexico on the next round. Mr. Aderholt. Mr. Fortenberry. FSA COUNTY OFFICE CONSOLIDATION Mr. Fortenberry. Thank you, Mr. Chairman. Good morning, everyone. Thank you for appearing today. A number of years ago, I held a town hall meeting in Allen, Nebraska. It is a town of about 350 people. And about 40 farmers showed up at noon. And I determined quickly that I had inappropriately mis-timed that town meeting because an hour before had been the meeting to discuss the closure of the Farm Service Agency in that county. And so when that was done, everybody came on over to talk about it with me. Now, we got through that, that county agency was saved, and we actually were able to consolidate it with another nearby county, which at first evaluation did not appear as an office that would be necessary to close. Anyway, the point being that we tried to work creatively through what was a consolidation that is difficult to adjust to, made necessary because of the tensions and difficulties that we all have in the budget. But at the same time tried to creatively meet the need of the constituent in the area that we are servicing. And so I think that is the spirit in which we have to all move forward here in terms of determining what is the highest and best uses of the limited resources that we have, and what needs to be transformed or renewed, we do so, and what needs to be changed, we embrace it and work creatively through it. FAS INFORMATION AND DATA COLLECTION With that said, in that regard, I want to turn to the Foreign Agricultural Service, a big portion of your work is statistical gathering, or at least it used to be as I understand that. Now, in this day and time in which we are integrated globally and, by the way, agricultural exports is essential to the well being of our nation. Let me point that out. It is one of the few things that we make on a large scale anymore, and it contributes significantly not only to our economic well-being at home but our positive trade balance as well. So your integration throughout the world, working on the ground, ensuring the robust nature of our export programs and ensuring the quality of the delivery of our food overseas is vitally important. A component of that is statistical gathering but again in this day and time in which we are globalized, in a previous time you were the only entity out there that could possibly do this. Large major agricultural--international agricultural organizations do their own statistical gathering. Talk about the mission of that component of what you do, and what possible changes could be made? Mr. Heinen. Well, thank you and thank you for your kind words about our efforts in regards to exports. Yes, one of the things that our attaches overseas do is collect information about production--productions and policies in their country. And that information is sent back, analyzed in Washington and contributes to our overall monthly publications of the WASDE report, the supply and demand estimates. You are absolutely right that many things have changed. I know in my first posting overseas in China, I was the expert in cotton. And I had London calling me and asking me about my estimates at that time. And things have really changed. And I would say we do not go out and do the kind of collections that we might have done at one time, kind of field surveys and things. We rely more on talking with others who have collected information, be they the host governments or other agencies. We use a lot more remote sensing, geo-spatial information. And we try to accumulate that in a much more efficient way and use other sources. But we still--there is still a great deal I think of confidence in the numbers that USDA puts out. Mr. Fortenberry. I guess that is the heart of my question. Do you still occupy a central place for the larger international agricultural community, trading, producers, markets? Is it a centralized core place as it once was? I am just not sure that is the case any longer. Ms. Heinen. I think we do still play a central role. There are other efforts going on that play other roles, but I think we play a central role in getting that confidence of what the situation is. CONSERVATION RESERVE PROGRAM Mr. Fortenberry. My time is running down so I do not mean to cut you off, but just get to a couple of other things. The CRP, I believe if I recall correctly, we topped out at about 39 million acres, and we have dropped down to about 28, is that correct? Mr. Scuse. Twenty seven, a little over 27. Mr. Fortenberry. Is that number based upon your trajectories, your predictions stabilizing there? Mr. Scuse. We have about three million acres coming out this year, so we may have a drop. Mr. Fortenberry. Not in that 27? Mr. Scuse. No, that is included in that 27. There will be about three million acres coming out. A lot of it will depend on, you know, where the commodity prices are, where the land actually is, but we may see an additional reduction. But we are going to start---- Mr. Fortenberry. What do your projections show over time as to where that number is likely to land? Mr. Scuse. Well, we have been seeing--I mean each year, we have been seeing a decrease in our CRP acreage. The President's proposal is 25 million acres. I think in the next two farm bills, the House and Senate version, they are looking at 25 million acres. That is probably close to where we will eventually be in the next couple of years. Mr. Fortenberry. Thank you, Mr. Chairman. Mr. Aderholt. Ms. DeLauro. CROP INSURANCE REFORMS Ms. DeLauro. Thank you very much, Mr. Chairman. My apologies, Secretary Sebelius is at Labor/HHS, so we are all kind of running back and forth here. So, I am going to use my five minutes, and I am going to ask--make it question concise, answers concise. Mr. Willis, your testimony notes that a ``reasonable rate of return for companies that provide crop insurance should be around 12 percent.'' So it appears that the Administration's proposal to establish this rate of return should not harm the ability of companies to offer these insurance policies. Is that correct? And I need a yes or a no. Mr. Willis. Yes. Ms. DeLauro. And your testimony indicates that the same is true for lowering the cap on federal dollars for the administrative costs of these companies? Mr. Willis. Yes. Ms. DeLauro. Is that accurate? Okay. I certainly hope that we can enact these kinds of commonsense savings in this effort. It is a program that has--estimated cost is about almost $59 billion, in any case. CROP INSURANCE OVERSIGHT Now, the GAO continues to find inadequate oversight of the Federal Crop Insurance Program. Crop insurance was one of the programs in GAO's ``Cost-savings and Revenue-Enhancement Opportunities Report.'' Your fiscal year 2014 budget request includes the lowest staff level ever. As a matter of fact, the level of your budget is the same amount that goes back to 2004. How will you implement the GAO recommendations to improve oversight with fewer RMA staff? How will this staff level affect your ability to strengthen oversight of the program? What has been done to improve the completion of field inspections after GAO's March 2012 report? How are RMA and FSA working together so this does not continue to fall through the cracks? How are you building on the existing data mining tools to better prevent fraud and abuse in the program? Mr. Willis. Anywhere you want me to start? Ms. DeLauro. How will you implement--you have lowered your staff numbers, I have talked about the size of your budget, the number of employees drops, lowest level ever, how are you going to implement the GAO recommendations to improve oversight with fewer staff? I read through the questions. So, let's go down the list. Mr. Willis. Primarily, through technology. We are using more data mining that singles out those areas, individuals who are of the highest risk to the program. We identify those. We do spot checks. One way we are leveraging the money we have is we are not just having our sister agency, the Farm Service Agency, do those spot checks. We are working with our companies. They started out with a pool last year. They are increasing that pool this year. So, we are leveraging those individuals. We are also improving our IT system. That should help reduce mistakes. It should have some edits in there where if information comes in that is faulty, it is rejected. So, I think a lot of it is going to have to happen through technology improvements. As far as the audit, I believe that is part of the new producer audit. What we have had is we have had the companies go back for I believe it is 2008 and 2009, and check 5,800 of those producers who were found to perhaps not be eligible for the new producer status. They should have finished that during the month of May. After that, we will send a new list for 2010, 2011 and 2012. And any producer who received the new producer status who should not, that will be corrected. Ms. DeLauro. What I will do is--I wanted you to answer this morning, but I am going to send each of these questions because I truly do want to know what the specifics are in terms of field inspections, et cetera, and the way in which we are going to do that. Let me ask you this question if I can. You have got 500 people and $75 million. I want your professional opinion. I want your professional opinion. Do you believe that you can adequately oversee this vast industry with that number of people and at this budget level? I want your professional opinion, and I do not know if your professional opinion represents what is represented here in the budget? Mr. Willis. We actually have 455 right now. Yes, I do, but I believe we will have to change the way we do business in some cases. We will have to use more technology to do that. Ms. DeLauro. Do you need more money to be able to do that? Mr. Willis. I think if we change the processes in certain cases we can do it. I think some of the examples with the data mining and leveraging resources, we have great private partners, I think we have to leverage them more. Ms. DeLauro. Let me just note for the record that the budget for RMA was $75 million in 2012. It was $71 million in 2004. So, it has not grown very much. In 2014, you are asking for $71.5 million for 2014, which actually puts you at about the 2005 level. With the growth of technology, with the increase in technology, and that--again, in order to deal with the vastness of this effort and to be able to do what the GAO has been asking to do is to take a look at waste, fraud and abuse in this program. You are fine with this budget and with the staff that you have, and that is adequate and that is your professional opinion? Mr. Willis. Yes. Ms. DeLauro. Thank you, Mr. Chairman. AGRICULTURAL EXPORTS Mr. Aderholt. Let me switch over and focus a little bit on the U.S. agriculture trade policy. It was talked about a little bit earlier, but against the backdrop of the poor economy over the last few years, we can take pride in the positive impact of U.S. agriculture exports. I along with many of my other colleagues believe there is far greater potential for growth of U.S. exports simply because 95 percent of the world's consumers live outside the United States of America. This is the second year in a row when we have not seen any new efforts, initiatives or plans by USDA to do more for agriculture exports. Just last month, OIG released a report on the matter of Foreign Agricultural Service reform, and said that FAS performance measures were not outcome-based and do not show how the U.S. is performing in given market compared to its competitors. My question would be does USDA have a recent comprehensive plan or strategy for competing in the global marketplace against the Chinese, Brazilians, Europeans or other countries that focus on increasing greater market share on behalf of their producers? Mr. Scuse. Well, thank you for recognizing the exports and the growth in the exports. As I pointed out earlier, the last four years have been the strongest that we have ever had. We have done almost a half a trillion dollars worth of exports the last four years. And when you look at this year again, we are looking at about $142 billion in trade, which would give us another record year. I think if you look at what the Administration has done, we have the three FTAs that were passed. Congress passed the Korea, Panama and Colombia FTA. We have already seen tremendous growth in those three countries already. Our exports this past year were about $7.6 billion. We are in discussions right now with the TransPacific Partnership. They are counting the United States, and I think the letter was just received yesterday where we are planning to engage Japan for inclusion in the TPP. There is a tremendous potential, especially now with Japan as part of the TPP for agricultural trade to get through some of the differences that we have. The President also announced that we were engaging in the Trans-Atlantic Trade and Investment Partnership with the EU. The EU collectively is our fifth largest trading partner. We face many barriers today with the EU. And I think this is a great opportunity to break down some of those barriers that we currently are facing. So there is a strategy within the Administration for us to build on the trade, the successes that we have had the last four years in trade. And we look forward to working with the rest of the Administration, especially the United States Trade Representative's office to get these agreements through so that we can further agricultural exports for our farmers and ranchers. TRADE MISSIONS Mr. Aderholt. Can you tell the subcommittee in particular what USDA is doing in fiscal year 2013 and 2014 and beyond to become more active on behalf of U.S. interests overseas and beyond what your current technical analysis or assistance is doing? Mr. Scuse. Well, Mr. Chairman, I personally have led two trade missions the last year. I led a trade mission to China in March, which was the largest trade mission that we had ever done. I had accompanying me several State Departments of Agriculture. And in December, I led a trade mission to Russia. Again, with 21 United States companies, and I believe five State Departments of Agriculture. We have a trade mission lined up for I believe the second week of June to Turkey. There has been a great deal of interest with again the State Departments of Agriculture, as well as other industry to participate in this trade mission. We are also working very hard with different groups on the trade shows, which is part of our MAP program. So, we are working very hard to further U.S. trade. And I think if you look at what has happened the last several years, that is the result of the work and cooperation between us and the commodity groups, as well as others, to promote U.S. agricultural products. AGRICULTURAL IMPORTS Mr. Aderholt. As we have here just in the last few minutes talked a great deal about the growth and the overall success of our agricultural exports, USDA's February ERS Report on Agriculture and Trade predicts that U.S. agriculture imports will also be at record levels. The report estimates that agriculture trade balance will be the lowest since 2009. What can USDA attribute this trend to? And should U.S. producers be concerned about the loss of the domestic share? Mr. Scuse. I do not think so. If you look at the types of products that we are importing into the United States, and if you look at the time of year that we are importing those products, for the most part a lot of them are products that we are not currently growing in the United States, especially those particular times of year. So, I do not see where our producers should be that concerned. Yes, there might be certain areas, certain segments of agriculture where there will be competition, but for the most part we are also exporting a great deal of products that we are importing, but at a different time of year. Mr. Aderholt. What are some examples of the imports you are talking about that would not compete with our growers? Mr. Scuse. Well, if you look at from our South American countries, if you would look at the grapes and the strawberries, and the different types of fruits and vegetables that would come from other countries but come during winter months when our production would be at its very lowest, if at all. So that is an example right there of where we are not having the competition. Mr. Aderholt. And you attribute that to we are doing that more now than we used to? Mr. Scuse. Yes, our demand for fruits and vegetables is increasing in the United States. If you look at what we are importing. Our demand from our consumers is also increasing just like many of the countries throughout the world. Their demand for our U.S. products is increasing. Mr. Aderholt. Thank you. Mr. Farr. IMPORTED FLOWERS Mr. Farr. On that trade issue, I have a particular concern about flowers because I represent a lot of flower growers. Do you have flowers in the Department? Do you have flower displays, floral displays in the Secretary's office or anything like that? Your office? Mr. Scuse. We did yesterday. Mr. Farr. Are those flowers from the U.S.? Mr. Scuse. Yes, sir. Mr. Farr. Are you sure? Mr. Scuse. I think the flowers that we had on display yesterday were from---- Mr. Farr. Not just yesterday. Mr. Scuse. Well, I cannot say forever or for last week or the week before, but I think the flowers that we had yesterday were. Mr. Farr. Could you check on that policy because we are trying to get--and the White House has a policy about serving all the food and wines have to be American, but they have in the past had at the expense of American flower growers, have had all these imported flowers. I would like to see some leadership on making sure that at least our government agencies are using domestically-grown flowers because we produce a lot of them. INSURED CROPS What crops are insured? Mr. Willis. We have about I think it is--is it 300? About 300 crops are insured, sir. Mr. Farr. Are insured? Mr. Willis. Yes, sir. Mr. Farr. Which ones are not? How many are not insured? Mr. Willis. What we will find is a crop might be insured in one county, like an apple, because you have a lot of apple production. You have the data you need to create a policy. But you might move to a different county, and the apples are not covered because there is not the historical production data in those counties. So, you will have a lot of fruits and vegetables in particular that are covered in certain areas, but not covered in certain areas because the data is not available. So it is going to be where the crop is grown a lot. Mr. Farr. Well, we grow 85 crops, and you can find anybody who will tell you what crop they are going to grow. They are going to grow three crops a year, they will not tell you what they are going to grow, what their next crop will be. So you do not have I mean those standard records. Why do we not have some data that allows them still to be in an insurance program? Mr. Willis. I am not sure I followed that question, sir? Mr. Farr. Take raspberries. Well, raspberries are a more permanent crop. Mr. Willis. Yes, sir. Mr. Farr. But lettuce? Mr. Willis. If there is a county where there is a lot of lettuce growing, and it---- Mr. Farr. There is, it is called Monterey County. It grows 80 percent of the lettuce in the United States. Mr. Willis. I think if the producer--many counties, and especially in California with lettuce, I actually visited there a few months ago, they do not want crop insurance simply because in the lettuce market in particular, they are more concerned about the price fluctuations, and they often destroy their crop when the price gets too low to keep the market in balance. And they have actually not asked for crop insurance for those crops. But where people ask for it, and there is data, we want to expand. We do not want to have people who grow a crop not have crop insurance available to them. Mr. Farr. What about food safety insurance for contamination for recall, like spinach? Mr. Willis. As I understand it, we do not have the legislative authority to do that right now, sir. Mr. Farr. You need legislative authority for--to sell--but the market will sell it or they only sell insurance that is covered by--subsidized by USDA? Mr. Willis. As I understand it, the Federal Crop Insurance Act does not allow the Department of Agriculture to work with our private partners and offer crop insurance that would help in cases of a recall, I think is a common example, or those types of situations. NON-INSURED CROP ASSISTANCE PROGRAM Mr. Farr. But if there is a natural disaster and something gets wiped out, then they can get access to the non-insurance, right? Mr. Willis. If there is a natural disaster, we cover those types of losses. And if the Crop Insurance Program does not cover a crop in a county, as we talked about, the Non-Insured Crop Assistance Program, administered by Farm Service Agency, will step in and cover those crops. Mr. Farr. What are the requirements for that? Mr. Willis. For the Non-Insured Crop Assistance Program? Mr. Farr. Yes, what are the requirements to trigger the authority to use that insurance? Mr. Willis. The primary requirement is that the catastrophic level crop insurance policy that we would offer is not available for that crop in that county. Mr. Farr. And it does not have to be, for example, you could not collect on the recall of the spinach? Mr. Willis. It would again only be for losses from natural disasters. Mr. Farr. And natural disasters has to have enough loss to trigger, it is a formula for declaring a natural disaster. It is not just any time you want to declare it. Mr. Willis. They use a formula. Mr. Farr. They use a formula of loss, of value of loss or life loss. The governor of the state has to declare it first, meeting state standards. Those state standards have to meet federal standards. And if they meet them, then there is a federal declaration. And you need that before you can trigger the insurance. Mr. Scuse. No, sir, for the NAP insurance, you do not need a declaration--a disaster declaration to be covered under that. It is catastrophic insurance, so you have to have a 50 percent loss or 55 percent reduction in the price. Mr. Farr. Well, we had that with spinach, and there was no way of getting any help. Mr. Scuse. But the producers have to sign up for that insurance. Mr. Farr. But that insurance is not sold, he just told us. Mr. Scuse. But through the county office, they could have been insured through the NAP program. Mr. Farr. I do not think they have the actuarial information to provide that insurance, but I would like to look into that. My time has expired. Mr. Aderholt. Mr. Nunnelee. MECHANICALLY-SEPARATED POULTRY Mr. Nunnelee. Thank you, Mr. Chairman. I'd like to go back to a lot of questions that Mr. Bishop started concerning the HACCP Rule on poultry. I understand you answered Mr. Bishop's question that it effects approximately $300 Million worth of poultry exports. Do you believe there will be any retaliation from countries that are importing this poultry, if this rule were to be implemented? Mr. Scuse. I don't believe so. I think this is just the way we are trying to protect our trading partners as well as the industry. So I don't know that there would be any sort of retaliation for trying to protect our trading partners. COMMUNICATIONS ON AGRICULTURAL EXPORTS Mr. Nunnelee. And then Mr. Bishop asked about communication between FSIS and your agency, specifically, as it related to the HACCP plan. I am interested more in general communication between the various agencies, you know, with USDA or outside USDA as it relates to agricultural exports as they consider regulations. Are you comfortable with the level of communication that exists, or should there be changes made as agencies are considering regulations affecting Ag exports? Mr. Scuse. Yeah. I appreciate the question, and it's one that we get often. I think we are working better together now than we probably ever have. I know with the FSIS with Under Secretary Hagen there, there's been a lot of involvement and back and forth between her agency and mine on issues. We are working very closely with the United States Trade Representative's Office on all different areas, not just exports, but some of the trade barriers that we have with some of the other countries. So I think we have a really good working relationships with our sister agencies right now in trying to not just protect our consumers, but also make sure we are furthering U.S. trade as well? ACREAGE CROP REPORTING STREAMLINING INITIATIVE Mr. Nunnelee. Then, let me shift gears. We have talked the last couple of years about redundancy in various reporting requirements. And we talked a bit last year about some successes that we have had, even in areas we had four different agencies giving different labels to the same parcel of land and how farmers tell me they are sending the same data set to numerous agencies, even within USDA. And I understand you are working on that. Can you just tell me what progress we have made since we met last year? Mr. Scuse. Again, we have made tremendous progress. Just the ability to get everybody to sit down in the room and come to an agreement on the identifier as well as the reporting dates, that was a big step. But, I mean, as I pointed out earlier, the acreage crop reporting streamlining initiative, we are starting a pilot program this year. If that pilot program goes well, then we can incorporate it into our MIDAS program where we are only going to have the one-stop shopping. As a farmer, myself, I don't like the fact I have to go give a report to the Farm Service Agency and my crop insurance agent. So I understand the importance of one-stop shopping and eliminating the redundancy in some of these areas, but we are making progress. You know, I would hope that next year I could tell you that we are beyond the pilot project, but a lot of this also had to deal with getting the MIDAS project up and functional so that we could go ahead and do the acreage crop- reporting streamlining initiative and eventually incorporate it. So I understand your concern. Mr. Nunnelee. And I would just encourage you to continue to work diligently in that area. Earlier this year, Secretary Vilsack testified before this Subcommittee and talked about categorical eligibility for Food Stamp recipients. And the response was, well, we don't want these recipients to have to go in and fill out the same information numerous times for various benefits. And I understand that. I would just encourage you that if we were going to do it for the ones getting Food Stamps, let's make sure we tip to eliminate that redundancy for the ones growing the food that they are eating. Mr. Scuse. You have my commitment. Mr. Nunnelee. Thank you. Mr. Aderholt. Ms. Pingree. INSURED CROPS Ms. Pingree. Thank you, Mr. Chair. Just one more thing on crop insurance, and I appreciate there have been a lot of interesting conversations. So this is about diversified crop insurance. Certainly, a lot of farmers in Maine have gone to more of a diversified crop, several acres of mixed vegetables or different kinds of farm inputs, and it has been very successful for them. In the market, this means that a lot of farms don't look like they used to where you just evaluate the value of soybeans or cotton or something in particular, but what I found during my brief tenure here in Congress is there are a lot of holes in the coverage available to diversified farmers. It should not be available to some farmers. It should be available to all types of farms, and it shouldn't insure the whole farm. I know that in some states RMA has made available the adjusted gross revenue insurance, and the variation is called AGR Lite. But these seem to be very undersubscribed programs, very hard to use. So can you talk about some of the challenges in developing and administrating these programs, and what other work is being done since this is insurance that actually meets a growing number of farmer's concerns. Mr. Willis. Yeah. Consistent in a way with I think your Local Foods Farm and Jobs Act that you have where you encourage us to work on a whole farm type policy. We have actually met with some of the stakeholders in that area, trying to determine what they do not like about the current policy you mentioned: Adjusted Gross Lite and AGR. In trying to figure out how we can develop a policy that works for them, obviously, this is an area where we have room to expand. We have room to improve our programs there. One of the things I think would be a first step there, actually, was language in the House passed Farm Bill, the buyout for the Non-insured Crop Assistance Program, where producers would have better coverage under that. But what we are going to do on our end instead of waiting for a Farm Bill to pass, we have the authority to try to expand this and try to improve this program as it is. We are going to try to first identify what exactly the problems are, because it's a growing segment, but they are all very different too. They are not the same. See if there is a way that we can address their needs. Ms. Pingree. Great. Well, I hope you will keep me in the loop. I am glad you are trying to make some progress, and it's good that everything doesn't wait for the Farm Bill, since we are all waiting for the Farm Bill. FSA MICROLOAN PROGRAM One other question is just on the micro loan program, the FSA loan is just a micro lending program, as you know, and it's been a great interest again in people in my area. My understanding is that you made more than a thousand micro loans in the first two months in the program. 30 of those were in Maine. The design seems innovative. It reduces the paperwork. It's great for new and beginning farmers who often have very limited capital accessibility or resources. So I see that the direct farm operating loans are increased significantly by $200 Million in the President's budgets. What portion of this is likely to go to the micro lending program and how many farmers do you anticipated we might be able to serve in FY '14 if it goes through at this level? And what else can we be doing to support this? I think it fills a very important need, and I am glad to see we have been able to use it in my state. Mr. Garcia. Thank you for your question, Congresswoman. Yes, ma'am. The Microloan Program has been very successful since we initiated the program here in January. To date, we have been able to approve up to 1,800 microLoans for around $25 Million. About 90 percent of those loans have been issued to beginning farmers, so it has been a very important program. You mentioned some good aspects of the program: less paperwork. The loans are up to $35,000, and one of the major aspects of this program that producers were having difficulty in obtaining the loan was the experience eligibility of these loans. So, for beginning farmers, one aspect of the program is that they can seek the assistance of a mentor, another farmer that's been in business for a while to meet the eligibility. The funding for this program comes out of the regular, Direct Operating Loan funds. So it is just part of that funding that we received for our direct loan programs. Of course, over 60 percent of the direct loan operating funds go to beginning farmers and SDA producers. So we will continue working with our Microloan Program. We have not set a cap. In other words, we have not targeted X amount of dollars within our operating loan budget for micro loans. We have been making loans up to $35,000 in the past, but with different requirements than this particular program. It has been very successful for us. Ms. Pingree. So, even though you don't have a cap, just to clarify, if this number is expanded, there is a likelihood you would be able to see far more of these loans if they continue to be as popular as they are. Mr. Garcia. Yes, ma'am. They continue to be very popular within the first month. Gosh! We approved very many loans and it is just consistently growing. And this has really helped our small farmers and beginning farmers. Ms. Pingree. Right. Thank you very much. Mr. Garcia. So a successful program. Thank you. Mr. Aderholt. Mr. Bishop. Mr. Bishop. Thank you very much. STACKED INCOME PROTECTION PLAN Let me try to get in two, quick questions. And before I get to tomato dumping issue, I want to talk about cotton and the STAX program. The House Ag Committee and the Senate Ag Committee in the version of the proposed Farm Bill included a new proposed stacked income protection plan called STAX. And it was designed to provide a fiscally responsible and effective income safety net for cotton producers as well as address issues raised about the Brazilian WTO case. But it is not my understanding that wheat, corn, soybean and possibly other commodity groups have expressed an interest in being included in the STAX cotton proposal or similar proposal rather than participating in the proposed House-Senate commodity programs. Any thoughts about that? Mr. Scuse. There is an issue with the STAX program as drafted in the House in relationship to the reference price for the program. If there is a reference price included, that would cause us problems with our WTO commitments for Brazil. So the reference price inclusion is an issue for that program. Mr. Bishop. Thank you. MEXICAN TOMATO ANTI-DUMPING CASE Ms. Heinen, of course the Mexican tomato dumping issue and the Department of Commerce's activities, I am sure you are familiar with that. What has been USDA's role in the matter and what is the Mexican Government's plan, if any, to stop tomatoes from being illegally dumped in our country? And is this the sort of issue that the U.S. could or should seek relief from before the WTO and are there currently any cases, which we brought against other nations pending at the WTO to protect American farmers? Ms. Heinen. Well, as you noted, this is in the hands of Commerce. And we were pleased to see that they were able to find an agreement to this antidumping case. There have been developments in the tomato industry since the last agreement was signed; and, so, I think it was appropriate that they looked at some of those and came up with new ways of trying to include more of the growers in Mexico, and as well as increasing enforcement. And the Mexican government has been a party to this in coming up with ways that they will increase enforcement and ensure that at least 85 percent, if not more people are signed up. There is also use of some of our instruments here. So, all in all, we hope that this agreement will bring a level playing field to our growers in Florida as well as in your state of Georgia. CORN CROP Mr. Bishop. Thank you. Let me talk about corn for a moment. It has been estimated by some private analysts that planted corn acreage could exceed 95 million acres this year. Much of this increased acreage will likely come with expensive soybeans, which is a critical crop for domestic livestock and poultry, and for export. Also, corn yields have stagnated, and if not in fact declined in recent years, although weather has perhaps has had some impact on that. As the Department developed contingency plans, if there's a continued shortfall in the corn harvest of this fall, for example, are there non-environmentally sensitive acres in the CRP program that could be made available for crop production, what can USDA do to make sure that the supervised corn inventories and corn prices will return to a more normal, more acceptable levels in the coming years. Mr. Scuse. Congressman, we have one of the worst droughts in the history of the nation last year, I think everyone would agree. But we still ended up with the eighth largest corn crop in the history of the United States. Technology has brought us a long way, and if you will look at what the market has done in the last few months, you have seen the corn price drop from its high last summer of over eight dollars. So the market, I think, is adjusting, especially to the supply, the latest supply side, as well as those planning intentioned reports. We believe that we will have an adequate supply as we stated last summer. We thought that we would have an adequate supply in spite of the drought. So we anticipate having adequate supplies of corn and soybeans, again. Technology has gone a long way to help us get to where we are today. Mr. Bishop. We are looking--going years forward, though. I mean, obviously, with 95 percent more acres planted that you are going to have a bigger supply. But that is temporary, and if land is being stagnated by over production of corn, what is going to happen in out years? Mr. Scuse. If you take away last year's drought and you look at the trend line for corn yields, they skyrocket. We have gone from 125 bushels to the acre just a few years ago to before last year. I think it was over 160 bushels, so the technology is boosting our yields at a tremendous rate, and we anticipate that to continue. CROP INSURANCE IMPROPER PAYMENTS Mr. Aderholt. Let me switch over a little bit and talk about in proper payments. Last month, USDA's OIG issued a report entitled, ``U.S. Department of Agriculture Improper Payments Elimination And Recovery Act 2010 Compliance Review for FY 2012.'' According to this report, USDA delivers approximately $144 billion in public services annually through more than 300 programs. Of the 29 component agencies and offices that operate base programs, seven component agencies, including RMA and FSA, currently administer high risk programs that are vulnerable to significant and improper payments. USDA estimated in FY '12 that these agencies' 16 total high risk programs made $5.5 billion in improper payments. That's a 5.11 percent error rate. Programs in this mission area don't come close to the school lunch or school breakfast programs, but it is imperative that we reduce or eliminate improper payments across the board, regardless of what they are. In regards to RMA, the report says, ``RMA reported that FCIC improper payments were approximately $173 million, which was a 4.08 percent error rate.'' However, because of RMA's sampling methods, OIG believes this estimate has been understated. The question is what is RMA doing to tackle this problem, and when do you expect to achieve improvements in this particular area? Mr. Willis. Well, first of all, when spending taxpayers' dollar, one dollar improper payment is too much. So we take this very seriously. As you mentioned, last year's improper payment rate was 4.08. Some of the steps were taken to try to improve that. The new database, we think, that this will keep better track of yields, which will help us on that; but, also, with edit checks, if something is reported that doesn't fit in the system, it will get kicked out, and that will reduce our improper payment rate as well. Precision agriculture technology: We are trying to move to where farmers who use that technology, yield monitors, acreage reporting, can do that more and more. We feel that will kind of eliminate opportunities when improper figures can be entered in and help us to improve integrity of the program. Finally, in cases when there is a widespread problem, we have the ability to deny reinsurance to the companies if they are responsible for those problems, which means that if there is a loss, they are on the hook for that loss. So I think we are trying a lot of different steps to try to reduce that rate, but we share your concern. We would like to get that down from where it is today. Mr. Aderholt. Oh. Let me just mention this. There was a Congressional Research Service Report from January that said some agencies, including USDA, have indicated that statutory or regulatory barriers have interfered with the ability to perform recovery audits. For FSA repayments, does the agency have difficulty recuperating the funds? Mr. Scuse. We identified, I believe, because of the adjusted gross income--we identified approximately $135 million worth of receivables. And we have recovered so far $110 million of that money. So we are working and pursuing those accounts that are owed. Mr. Aderholt. Very good. CRP ADMINISTRATIVE COSTS The budget request proposes to tap $50 million from the Environmental Quality Incentives Program, and that is to cover FSA's salary and expense cost of operating the conservation reserve program--the CRP. This is the first time that FSA has proposed to do this. I wonder if you could tell the subcommittee what's the background of wanting to do this. Mr. Scuse. Well, in many instances we have been conducting these programs and have not gotten the compensation from those programs for the cost of running and administering them. And so we're trying now in light of the budget situation to look at, make sure that we are recovering the expenses that we are incurring in some of these programs. I mean we also do with the inspections with the Risk Management Agency. So we are looking at ways that we can make sure that when we go out and do those field audits, that we are going to actually recover the cost for doing those audits. So that is an example of where we wanted to make sure we are recovering our expenses. Mr. Aderholt. Okay. My time is up, but I may want to follow-up a little bit later on that. Mr. Farr. Mr. Farr. Thank you, Mr. Chairman. Mr. Bishop, I think if you want to stop the dumping of tomatoes, just have the American tomato growers produce a tasteful tomato. I think the first one that comes up with a good tomato will sell a lot of them. I am sad that Mr. Nunnelee left because one of the things I was glad to hear was he took responsibility for the sequestration, they have been trying to blame that on the President and everyone else. To think that sequestration had very little impact because you did not have to lay off or furlough people is a misnomer, because you point out in your testimony that the Secretary had interchange authority, to transfer funds from direct payment programs, the tobacco transition program, marketing access loans, the loan deficiency payments, storage and handling, the NAP and MILC, to back fill amounts sequestered. You had authorities that other Secretaries did not have. I am sure it had some impact because I know the five percent cut in our own budget, our Congressional Office budget, had huge impacts. I think we are going to see as California did after living with these furloughs, the voters got upset and just went to the polls and then raised taxes. It was not done by the legislature. It was done by the vote of the people. CROP INSURANCE UNMET NEEDS Mr. Willis, you have been a staff member on the Hill. You know legislators are always looking for ideas for legislation. I would be very interested if you could give me a letter of your feelings about unmet crop insurance needs. We are moving into a new era of food safety. I think the recall of spinach that I saw, which was really a voluntary recall. We had a county that probably lost $100 million. Spinach growers, that is all they grow. Their insurance, if they had it, would not cover it because it was voluntary. Because it was not a disaster, we could not collect any of the programs here. You have these kinds of issues that are coming up, incidents that are coming up where there is no insurance. I am sure you know lots of those things. It would be appreciated if you could give me your professional judgment on what are the unmet needs in sort of the whole generic of crop insurance, all crops. [The information follows:] RMA is researching information to give a proficient response on unmet crop insurance needs. The information will be provided to the Subcommittee as soon as it is available. Mr. Bishop. Tasty tomatoes, too. Mr. Farr. Insure a tasty tomato? NUTRITIONAL QUALITY OF FOOD AID I want to ask a question about food nutrition. I appreciate all the work the USA does to help feed the poorest and most vulnerable people in the world. To make sure that we have the biggest impact, we need to have a high quality and nutritional food included in our donations to hungry families and children in emergency situations. I am sure you have seen the studies that both Tufts University and GAO did looking into the cost effective ways to better match the nutritional quality of U.S. food aid with beneficiaries, and make sure that the food aid recipients are actually getting their nutritional needs met by our food assistance. My question is what else can USDA do to improve the nutritional quality of food aid to make sure that the most vulnerable populations are getting the nutrition they need, to not just survive, but to thrive? I would be particularly interested in what can be done for children, women, and expecting mothers. Ms. Heinen. Thank you. Congressman, we could not agree more, it is not just a matter of food but the type of food. Currently, under our McGovern-Dole Program, we are doing pilot projects in five countries with six new products to try to meet those needs more precisely for those populations. We are looking at supplements that will increase Vitamin A, or Zinc, and some of these other things that are lacking from their diet. Mr. Farr. Are we just going to put vitamin pills in? Mr. Heinen. No. They are different products. There is one that is a peanut product. There is one that is a turkey spread that is part of the diet for the school feeding. All of these have different nutritional components that we are trying to match to those specific problems that we see in those areas, which might be stunting, anemia, lacking B-12, different things they are missing. We are trying to better match what the problems are within the areas with different types of nutritional supplements in the diets that we provide in the school feeding program. We think some of these might be used more widely in some of the other feeding programs as we see what kinds of effects they might have. Mr. Farr. I would be interested in that work, if you could send us a memo on it. Ms. Heinen. I would be happy to. [The information follows:] [GRAPHIC] [TIFF OMITTED] T2639A.041 [GRAPHIC] [TIFF OMITTED] T2639A.042 Mr. Farr. I would appreciate it. Thank you. Mr. Aderholt. Mr. Bishop. EXPORTATION OF U.S. PEANUTS Mr. Bishop. Thank you very much. I was glad to hear you mention the health benefits of peanuts. I was pleased to learn that the Foreign Ag Service was a major impetus behind the re- opening of the foreign market for U.S. peanuts in Poland. That was a major coup. On behalf of the peanut producers in the Southeast and Southwest that produce the majority of peanuts, and of course, in Southwest Georgia, Alabama and Mississippi, we all thank you. With that said, I am told there may be further opportunities to expand the exportation of U.S. peanuts as well as cotton to other former Communist countries in Eastern Europe. Are there any specific efforts underway in this regard and has the MAP Program been an effective tool for you for product expansion in Eastern Europe? Are there any efforts to expand peanut exportation globally? Ms. Heinen. Thank you for that. It was the hard work of our attache, I think, in Poland, that really made the difference there. We do think the MAP Program has been highly effective in matching what we as a Government can do with what the experts in the industries can do. We worked quite closely with the Peanut Association here to find opportunities for them in whole peanuts or in products, in food aid, in supplements. I think Europe is still a good possible market, Eastern Europe. I hope some of the barriers will come down that we see in peanuts. Mr. Bishop. Are you familiar with peanuts and China? Ms. Heinen. China is a major producer of peanuts as well. We often have problems with things in China, and it is just a matter of working through the specifics of the commodities, the regulations. We still have hopes for that market. Mr. Bishop. I recently got some information that they were doing quite a bit of acquisition, and then all of a sudden, they stopped short. They have some delay, and the thought is it has something to do with the peanuts being sent through Vietnam, and they were having some issues with regard to the origin of it. Are you familiar with that issue? Ms. Heinen. I am not but I would be happy to look into it and get back to you with specific information. Mr. Bishop. Thank you. This is something that is within the last six weeks. TEMPORARY WORKER PROGRAM Mr. Aderholt. Let me turn just a minute to an issue that has got a lot of attention on Capitol Hill over the last several years but in the last few months, it has really been a hot issue. That has been the immigration issue. We are seeing signs that the House and Senate could take up legislation to work on some of these issues. I know our Temporary Worker Program is very important to agriculture. We do need policies in place to encourage the flow of labor in and out of the country that is legal. Any comprehensive immigration reform should allow an increase in H-2A and H-2B Visa's that reflect the needs of our industries and especially expediting the process during the agricultural seasons. The question that I want to focus on is the comments that the Secretary supposedly made in a speech to the North American Agricultural Journalists as he was quoted in the Hagstrom Report saying USDA could partner with Labor and local USDA offices, and they could track workers, once they entered the United States. Since your agencies would likely play a major role in that effort, could you talk a little bit about what the Secretary had in mind and what he envisioned? Mr. Scuse. I think as you pointed out, immigration reform is extremely important to the agricultural sector. We have different sectors within agriculture that are heavily dependent on a worker, guest worker workforce. I think what the Secretary had in mind, when you look at our farmers and ranchers across the United States and you look at the comfort level they have in coming into the Farm Service Agency Office, they would feel much more comfortable visiting the County Farm Service Agency Office to do a reporting on the workers that they need for their farms and ranches, rather than going to another Federal agency office. I think that is what the Secretary had in mind, to use our offices because of the comfort level the agricultural community has with it. Mr. Aderholt. Is such a proposal possible under the make-up of staff and other resources available in the field? In other words, would additional tasks take a field office away from their primary responsibility? Mr. Scuse. I do not think so, Mr. Chairman. I think we would be able to do that task with the current workforce that we have, even though in the last ten years we have downsized our workforce by 32 percent. I still think with the workforce that we have and with the technology that we now have in place, I believe we would be able to do it. I am going to take this opportunity to brag. The Farm Service Agency, those county offices and those staff in those county offices are second to none. They are truly outstanding people who do a great job every day for our farmers and ranchers. Mr. Aderholt. Thank you. Mr. Fortenberry. Mr. Fortenberry. Thank you, Mr. Chairman. I agree with that last assessment. The Farm Service Agency personnel are very, very dedicated, as are many of the various persons who are out in the field. They have an affinity for the community. They work hard. I know any change is difficult a lot of times because these are friends and neighbors of a lot of folks in particular counties. FARMER TO FARMER PROGRAM A more narrow question, it is my understanding it is not directly under your jurisdiction, but if you have any input on it, the Farmer to Farmer Program is an USAID administered program, as I understand it. Do you have any interaction with that particular program and have seen the benefits of it? Ms. Heinen. We do not have formal interaction in Washington but I have in my experiences overseas worked with a number of people who were part of that Farmer to Farmer Program, and learned things about what they were doing out in the field and worked with them to tell them what we see in the field. OLD AND NEW OPPORTUNITIES Mr. Fortenberry. Here is a broader point. I have asked everyone who has been here, including the Secretary, throughout these hearings, the same question. It is related to what I said earlier. We have got to be about the business of being entrepreneurial and creative, letting go of what was old in order to reform to meet the growing change in demands of that which is new. Sometimes when budgets are under stress or tension, it forces creativity. One of the ideas, it seems to me, to be important for a whole variety of reasons, not only in terms of promotion of our own products, person to person exchange, building of relationships that has national security implications, has trade implications, but to take the farmer who is interested in giving something to another person maybe in an impoverished area of the world, perhaps consider that as a component, if you would, of the Foreign Agricultural Service or in some way integrated into your efforts. I think it is one of those areas that we could look at that meets multiple objectives of what agriculture is already doing, not just in terms of trade policy and economic well being for us and others, but also the building of relationships to the transfer of real means of assistance to other people. It builds out their capacity, it ensures that we have not only communications but trust. That is essential to international stability. That is essential to our national security. We have 12 Nebraska National Guard members, for instance, right now who are farmers or have farm backgrounds in Afghanistan, some of the last troops that were there trying to build out economic capacity. This is related in more ways than just to our trade. It is related to the broader purposes of Government. As we are all examining how we get away from stove piping and silos and think about broader implications, here is what I am submitting to you as an idea of a particular program that has some history, that might be a way to think creatively to achieve these other objectives as a component of the Foreign Agricultural Service. Mr. Scuse. We do have two other programs. We have the Cochran Program where we bring Government officials from foreign countries in here to train them on ways that we do things here in the United States through our regulatory process and others. We also have the Borlaug Program where we will bring scientists and researchers from other countries into the United States to work with our scientists and researchers on projects. I do not want you to think we are not working with the other countries. I get your point. Farmer to Farmer would be another very good way to do that. There are programs that we do have where we do bring people in. Mr. Fortenberry. Would you take that idea back and ruminate on that? Let's see if we cannot develop something here that makes sense for all the various objectives I laid out. Could we do that? Mr. Scuse. Yes. Ms. Heinen. If I might add, I think our farmers are some of our best envoys overseas. Mr. Fortenberry. There you go, that is what I was looking for. Ms. Heinen. Many of our cooperator groups do take farmer groups overseas. INTERNATIONAL FOOD AID Mr. Fortenberry. I recognize that and the benefits to that, we do not measure them. One more quick question, if I could, Mr. Chairman. Regarding the food assistance changes that you were discussing earlier in terms of delivery, changing the way in which we deliver in emergency situations, I think it is important to make sure that we still have an American brand on that. Again, we are delivering emergency assistance for the broader purposes of humanity, humanitarian reasons, trying to help people who are in need. That is our fundamental purpose. That is who we are as Americans. It does help, I think, if other people know this is coming from the generosity of the American taxpayer. Mr. Aderholt. Mr. Fortenberry, we will let you have the last word. Thank you. I appreciate the panel being here. Under Secretary Scuse, thank you for your work and your service along with each of you in your respective agencies and what you do for agriculture for America and around the world. Again, we thank you for being here, and we look forward to working with you as we continue on with the fiscal year 2014 budget. Thank you. Mr. Fortenberry. Mr. Chairman, I would like to thank you and the members of the Committee for a very good hearing. Thank you very much. Mr. Aderholt. Thank you. [GRAPHIC] [TIFF OMITTED] T2639A.043 [GRAPHIC] [TIFF OMITTED] T2639A.044 [GRAPHIC] [TIFF OMITTED] T2639A.045 [GRAPHIC] [TIFF OMITTED] T2639A.046 [GRAPHIC] [TIFF OMITTED] T2639A.047 [GRAPHIC] [TIFF OMITTED] T2639A.048 [GRAPHIC] [TIFF OMITTED] T2639A.049 [GRAPHIC] [TIFF OMITTED] T2639A.050 [GRAPHIC] [TIFF OMITTED] T2639A.051 [GRAPHIC] [TIFF OMITTED] T2639A.052 [GRAPHIC] [TIFF OMITTED] T2639A.053 [GRAPHIC] [TIFF OMITTED] T2639A.054 [GRAPHIC] [TIFF OMITTED] T2639A.055 [GRAPHIC] [TIFF OMITTED] T2639A.056 [GRAPHIC] [TIFF OMITTED] T2639A.057 [GRAPHIC] [TIFF OMITTED] T2639A.058 [GRAPHIC] [TIFF OMITTED] T2639A.059 [GRAPHIC] [TIFF OMITTED] T2639A.060 [GRAPHIC] [TIFF OMITTED] T2639A.061 [GRAPHIC] [TIFF OMITTED] T2639A.062 [GRAPHIC] [TIFF OMITTED] T2639A.063 [GRAPHIC] [TIFF OMITTED] T2639A.064 [GRAPHIC] [TIFF OMITTED] T2639A.065 [GRAPHIC] [TIFF OMITTED] T2639A.066 [GRAPHIC] [TIFF OMITTED] T2639A.067 [GRAPHIC] [TIFF OMITTED] T2639A.068 [GRAPHIC] [TIFF OMITTED] T2639A.069 [GRAPHIC] [TIFF OMITTED] T2639A.070 [GRAPHIC] [TIFF OMITTED] T2639A.071 [GRAPHIC] [TIFF OMITTED] T2639A.072 [GRAPHIC] [TIFF OMITTED] T2639A.073 [GRAPHIC] [TIFF OMITTED] T2639A.074 [GRAPHIC] [TIFF OMITTED] T2639A.075 [GRAPHIC] [TIFF OMITTED] T2639A.076 [GRAPHIC] [TIFF OMITTED] T2639A.077 [GRAPHIC] [TIFF OMITTED] T2639A.078 [GRAPHIC] [TIFF OMITTED] T2639A.079 [GRAPHIC] [TIFF OMITTED] T2639A.080 [GRAPHIC] [TIFF OMITTED] T2639A.081 [GRAPHIC] [TIFF OMITTED] T2639A.082 [GRAPHIC] [TIFF OMITTED] T2639A.083 [GRAPHIC] [TIFF OMITTED] T2639A.084 [GRAPHIC] [TIFF OMITTED] T2639A.085 [GRAPHIC] [TIFF OMITTED] T2639A.086 [GRAPHIC] [TIFF OMITTED] T2639A.087 [GRAPHIC] [TIFF OMITTED] T2639A.088 [GRAPHIC] [TIFF OMITTED] T2639A.089 [GRAPHIC] [TIFF OMITTED] T2639A.090 [GRAPHIC] [TIFF OMITTED] T2639A.091 [GRAPHIC] [TIFF OMITTED] T2639A.092 [GRAPHIC] [TIFF OMITTED] T2639A.093 [GRAPHIC] [TIFF OMITTED] T2639A.094 [GRAPHIC] [TIFF OMITTED] T2639A.095 [GRAPHIC] [TIFF OMITTED] T2639A.096 [GRAPHIC] [TIFF OMITTED] T2639A.097 [GRAPHIC] [TIFF OMITTED] T2639A.098 [GRAPHIC] [TIFF OMITTED] T2639A.099 [GRAPHIC] [TIFF OMITTED] T2639A.100 [GRAPHIC] [TIFF OMITTED] T2639A.101 [GRAPHIC] [TIFF OMITTED] T2639A.102 [GRAPHIC] [TIFF OMITTED] T2639A.103 [GRAPHIC] [TIFF OMITTED] T2639A.104 [GRAPHIC] [TIFF OMITTED] T2639A.105 [GRAPHIC] [TIFF OMITTED] T2639A.106 [GRAPHIC] [TIFF OMITTED] T2639A.107 [GRAPHIC] [TIFF OMITTED] T2639A.108 [GRAPHIC] [TIFF OMITTED] T2639A.109 [GRAPHIC] [TIFF OMITTED] T2639A.110 [GRAPHIC] [TIFF OMITTED] T2639A.111 [GRAPHIC] [TIFF OMITTED] T2639A.112 [GRAPHIC] [TIFF OMITTED] T2639A.113 [GRAPHIC] [TIFF OMITTED] T2639A.114 [GRAPHIC] [TIFF OMITTED] T2639A.115 [GRAPHIC] [TIFF OMITTED] T2639A.116 [GRAPHIC] [TIFF OMITTED] T2639A.117 [GRAPHIC] [TIFF OMITTED] T2639A.118 [GRAPHIC] [TIFF OMITTED] T2639A.119 [GRAPHIC] [TIFF OMITTED] T2639A.120 [GRAPHIC] [TIFF OMITTED] T2639A.121 [GRAPHIC] [TIFF OMITTED] T2639A.122 [GRAPHIC] [TIFF OMITTED] T2639A.123 [GRAPHIC] [TIFF OMITTED] T2639A.124 [GRAPHIC] [TIFF OMITTED] T2639A.125 [GRAPHIC] [TIFF OMITTED] T2639A.126 [GRAPHIC] [TIFF OMITTED] T2639A.127 [GRAPHIC] [TIFF OMITTED] T2639A.128 [GRAPHIC] [TIFF OMITTED] T2639A.129 [GRAPHIC] [TIFF OMITTED] T2639A.130 [GRAPHIC] [TIFF OMITTED] T2639A.131 [GRAPHIC] [TIFF OMITTED] T2639A.132 [GRAPHIC] [TIFF OMITTED] T2639A.133 [GRAPHIC] [TIFF OMITTED] T2639A.134 [GRAPHIC] [TIFF OMITTED] T2639A.135 [GRAPHIC] [TIFF OMITTED] T2639A.136 [GRAPHIC] [TIFF OMITTED] T2639A.137 [GRAPHIC] [TIFF OMITTED] T2639A.138 [GRAPHIC] [TIFF OMITTED] T2639A.139 [GRAPHIC] [TIFF OMITTED] T2639A.140 [GRAPHIC] [TIFF OMITTED] T2639A.141 Friday, April 26, 2013. FOOD AND DRUG ADMINISTRATION WITNESSES MARGARET A. HAMBURG, M.D., COMMISSIONER, FOOD AND DRUG ADMINISTRATION, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES JAMES TYLER, CHIEF FINANCIAL OFFICER, FOOD AND DRUG ADMINISTRATION, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NORRIS W. COCHRAN, DEPUTY ASSISTANT SECRETARY, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Mr. Aderholt. Good morning. I would like to welcome everyone to the subcommittee today. And I would like to welcome especially Dr. Margaret Hamburg, Commissioner for Food and Drug Administration. Joining the Commissioner today is Mr. Norris Cochran, the Deputy Assistant Secretary for Budget of the U.S. Department of Health and Human Services, and Jay Tyler, FDA's Chief Financial Officer. Welcome to all three of you. The work that you and your colleagues at FDA perform touches the lives of every American, and we appreciate the dedicated service that each of you perform on a day-to-day basis. With that said, there are many challenges that face FDA. Compounding pharmacies, drug shortages, foodborne illnesses, dietary supplements are just some of those challenges. From where I sit, I see another challenge, and that is the pace at which FDA moves guidance, rules, and regulations through the process. In addition to the budget request, I want to focus today on this bureaucracy that just can't seem to produce crucial guidance, even though the science is evident. For example, USDA's dietary guidance for Americans on seafood consumption for women who are pregnant have been in place since January of 2011. However, for the past 2 years, this subcommittee has repeatedly asked the FDA to finalize its seafood consumption guidance, with no indication of closure, because the issue is tied up in bureaucratic infighting at the Department of Health and Human Services. This type of delayed response causes frustration with Congress as well as the millions of women who need answers on this and other important matters. Turning to the budget, I don't quite understand why the budget was submitted so late, given the fact that the basis for the request was the fiscal year 2013 continuing resolution that was signed into law on September the 28th, 2012. The result is a simple repeat of last year's budget. This budget could have been submitted much earlier, and there would have been more clarity regarding the President's request than there are currently. On Monday of this week, we asked the Food and Drug Administration to provide something as simple as a table that shows the proposed changes between the final fiscal year 2013 enacted levels and the fiscal year 2014 budget request level. Other agencies within the subcommittee's jurisdiction provided that to the committee more than 2 weeks ago without us even asking them for it. Unfortunately, we just got the information from the FDA well after the sun went down last night. This is basic budgetary information that FDA should have provided to the subcommittee without asking, and FDA should provide it upon request without delay. Overall, FDA is requesting $4.7 billion for fiscal year 2014, of which $2.6 billion is in discretionary budgetary authority and $2.1 billion is in user fees. Once again, FDA is requesting new user fee authority for food imports and food facility registration and inspection. These particular fees total $226 million. These fees do not appear to enjoy the same level of industry support as the prescription drug or medical device industries gave to their programs, because the food industry believes this to be a food safety tax. It seems that FDA has failed to communicate to the industry what, if any, performance measures FDA would use in managing this program. These fees are not currently authorized, and the chance of Congress authorizing this, I would say, would be very slim. With that, I would like to turn it over to the gentleman from California, our ranking member, Mr. Farr. Mr. Farr. Thank you very much, Mr. Chairman. I also welcome the Commissioner here and want to thank her very much for coming out to the Salinas Valley to see how fresh produce is grown and produced right in the field. We are still talking about your visit and how you compared the fact that you had to dress up in a suit and a hair net and gloves in order to go into the fields, it was like going into an operating room. That is how we are trying to keep our fields very healthy and clean. Mr. Chairman, I think we have all criticized the administration for a late budget, but we also need to criticize ourselves. Congress never even produced a budget. We haven't had a bill out of this committee since 2012, and before that, the only time we had had it was in 2010. So, you know, the President is supposed to base his budget on what Congress approves the year before. I hope we can remedy that. I would also just suggest that I think we in this committee ought to give the FDA the flexibility, the authority to use the user fees. These user fees are being paid by the private sector to get a job done, and they can't get the job done because we have unintended consequences of budget cuts and sequestration. This is money that is in the bank, it is sitting there, and we ought to give it to FDA to use, as we have done for other agencies. We did it for our parks to allow them to keep the fees and use them. Look at the way we qualify to run for Congress. You have to pay a fee at the local registrar, and they get to keep that fee for running the elections department, and so on. This is a fee that has been collected. The private sector is going to get really frustrated, really discouraged that the government isn't being a fair partner. And I think, you know, if you believe in private enterprise, they are coming up with paying these fees because they want answers to their questions, and we ought to allow the Department to use the fees they are paying for that purpose. So I look forward to this hearing, and I think that is something we ought to try to work on as a committee. Mr. Aderholt. Thank you, Mr. Farr. Mr. Aderholt. We are fortunate to have the full committee chairman, Mr. Rogers, with us today, and I would like to recognize him for any opening remarks he may have. Mr. Rogers. Thank you, Chairman, for recognizing me. Good morning---- Dr. Hamburg. Good morning. Mr. Rogers [continuing]. Commissioner, and thank you for being with us today to discuss the fiscal 2014 budget request for FDA. In other subcommittee hearings, I have already lamented the fact that this budget request is woefully late and won't get our Nation back on solid financial footing. But we will persevere. Before I comment on your budget, let me hasten to thank you for FDA's recent decision that prohibits generic crushable OxyContin from coming to market without abuse-deterrent technologies. Unfortunately, drugs misused are a recipe for disaster. And advocates across the country salute you for your leadership in shepherding this landmark decision on generic painkillers. Thank you. As you know, the abuse of prescription drugs, particularly opioid pain pills, is our Nation's fastest-growing drug threat. So great, in fact, that your colleagues at the Centers for Disease Control have called this crisis an epidemic. Just as FDA must responsibly address other epidemics like H1N1 and public health threats like meningitis from tainted steroid injections, you must also closely examine drugs entering or on the market, including the prescribing patterns and potential abuse. Last week's decision by your agency will surely save lives, and I hope it is a sign of things to come as it relates to our Nation's very serious pain pill addiction. Undoubtedly, the FDA is a critical partner in getting this multifaceted health, law enforcement, patient access, and education issue under control. I am anxious to hear from you today about how we can build on this success story and what other steps FDA can take to beat back on the abuse of prescription medications, like rescheduling our most widely prescribed and abused painkillers--hydrocodone combination drugs--and limiting the indication for prescribing these powerful opioids to severe pain only. Now to your budget, Commissioner. The FDA is seeking nearly $4.7 billion, which is $622 million above the fiscal 2013 level. I should note, however, that this request assumes that sequestration for fiscal 2014 is undone--far from a given, considering the President's unwillingness to truly engage in discussions to address our real cost drivers without talking more about taxes. Toward that end, this budget assumes the inclusion of six new user fees, including one for registration of food facilities, a fee likely to be passed on to consumers. As you can imagine, this committee and the general public has little appetite for food fees. I am sure we will discuss this issue at length, as well as your recent comments about the effects of sequestration on food inspections and the recent court order for FDA to move forward on the implementation of the Food Safety Modernization Act. So we look forward to hearing from you this morning. Dr. Hamburg. Thank you. Mr. Aderholt. Thank you, Chairman Rogers. Mr. Aderholt. Just bear in mind, we have votes today. I don't expect votes to be called for close to another hour, so we should get well into the hearing and make a big dent into the hearing. And we will just see how long we go. Sometimes the floor schedule is very unpredictable, so it may be even later before we have votes. So, with that, your, of course, statement is entered into the record, but at this time we would like to recognize you for your opening statement and comments before we go into the questioning aspect of the hearing. Dr. Hamburg. Well, thank you very much. And good morning, Chairman Aderholt, Ranking Member Farr, and certainly Chairman Rogers, and all the members of the subcommittee. [The information follows:] [GRAPHIC] [TIFF OMITTED] T2639A.142 [GRAPHIC] [TIFF OMITTED] T2639A.143 [GRAPHIC] [TIFF OMITTED] T2639A.144 [GRAPHIC] [TIFF OMITTED] T2639A.145 [GRAPHIC] [TIFF OMITTED] T2639A.146 [GRAPHIC] [TIFF OMITTED] T2639A.147 [GRAPHIC] [TIFF OMITTED] T2639A.148 [GRAPHIC] [TIFF OMITTED] T2639A.149 [GRAPHIC] [TIFF OMITTED] T2639A.150 [GRAPHIC] [TIFF OMITTED] T2639A.151 [GRAPHIC] [TIFF OMITTED] T2639A.152 [GRAPHIC] [TIFF OMITTED] T2639A.153 I do want to congratulate you, Congressman Aderholt, on your new position as chairman. And I also do want to thank the subcommittee for your past investments in FDA, which have helped reduce the gap between our budget and the demands of our increasingly complex mission. Congress has given FDA the responsibility for a vast range of products that are central to the health, safety, and wellbeing of every American. From spinach and breakfast cereals, to vaccinations that save millions of children's lives, to new medicines to treat killers like cancer and heart disease, Americans rely on products overseen by the FDA every single day. We also recognize that those who produce our Nation's food and medical products are vital components of the U.S. economy, as is a strong FDA. History shows that when the public trusts FDA's oversight of the products we regulate, these industries flourish. Conversely, when products cause serious harm, it can result in severe economic damage across the industry involved, to offenders and nonoffenders alike. I want to mention some of our measurable accomplishments this past year. In 2012, FDA approved 39 novel medicines, the highest number in over a decade. And the majority of these drugs were approved in the United States before anywhere else in the world, some in as little as 3\1/2\ months. The number of drug shortages were cut in half compared to 2011. We successfully turned around a decade of lengthening medical device reviews and backlogs. Working together with 45 State and territorial partners, we have conducted more than 158,000 inspections of tobacco retailers to ensure that they are not selling cigarettes or smokeless tobacco products to minors. And we have published our first two food safety proposed rules as part of the implementation of the historic Food Safety Modernization Act. And I might add that FDA is a smart investment and a bargain. Consider that the products we regulate represent more than 20 cents of every dollar that consumers spend on products in the United States. But if you look at our budget, in terms of the BA or public dollars, every American effectively pays only about $8 a year for FDA services. And while FDA continues to oversee a multitude of products vitally significant to all of us, our job has become increasingly demanding. First, we are in the midst of dramatic changes in the way that foods, drugs, biologics, and devices are produced and reach the American public. We are witnessing revolutionary advances in science and technology that hold such promise to improve health and prevent disease, yet also bring new scientific and regulatory complexities. And we are facing the globalization of our food and medical product supplies, demonstrated by a quadrupling of imports over the past decade. FSMA Second, Congress has continued to expand our responsibilities with new laws, including FSMA, the most sweeping reform of our food safety laws in some 70 years; the Family Smoking Prevention and Tobacco Control Act, the landmark legislation giving FDA the responsibility to regulate tobacco products; and, most recently, the passage of the FDA Safety and Innovation Act, FDASIA, which, among other things, creates two new user fees to speed the review of more affordable versions of drugs, essential to holding down healthcare costs, and new regulatory strategies to increase our efficiency and effectiveness. As we look at our fiscal year 2014 budget needs, we must respond to the demands of complex and increasing responsibilities while recognizing the realities of a constrained economic environment. Thus, we must focus on a set of key mission-critical programs and activities and leverage limited resources to the greatest degree possible. The President's proposed fiscal year 2014 budget request is for over $4.6 billion, which includes $2.5 billion in budget authority and $2.1 billion in user fees. This represents an $821 million increase over fiscal year 2012, $52 million of which is budget authority and $769 million in user fees, including two new user fee proposals for food safety and cosmetics. A central component of the budget request, as noted, supports our efforts to implement FSMA and create a modern food safety system based on prevention rather than responding after a problem occurs. FDA is committed to working with industry and our partners at all levels of government to put in place the necessary risk-based, flexible system that recognizes and respects the varying needs of different components of the food enterprise. I want to thank you for the $40 million in one-time, no- year money that was part of the recent CR, which will help us to continue our outreach and activities. For fiscal year 2014, our budget request is $43 million and $225 million in proposed user fees for food facility registration, inspection, and imports. FOOD SAFETY As you know, Congress has long endorsed the use of fees to help support government agency work, especially work that meets specific industry needs as well as benefiting the American public. A broad coalition of industry groups supported enactment of FSMA because they knew they would benefit from a food safety system that works effectively to prevent food safety problems and strengthens consumer confidence in the food supply. We cannot build this modern food safety system, including the new mandates for import oversight, without the funding laid out in the President's budget. We look forward to dialogue with Congress and all of our stakeholders to shape a fee proposal that is fair, workable, and advances both industry and public interests. In addition, we must respond to and harness modern science to enhance the pipeline of new and better, safer medicines and vaccines. We are asking for $18 million to continue our efforts to consolidate FDA scientists and other professionals in the White Oak campus, including requirements to outfit FDA's three bioscience labs and other facilities. Without these funds, the labs cannot be used and the $300 million cost of constructing them will be wasted. We are eager to continue this and other important work. I believe our fiscal year 2014 budget efficiently targets our needs, focusing on programs that are essential to providing Americans with safe food and effective medical products that they expect and deserve. I look forward to answering your questions today and working with you in the coming year. Thank you very much. Mr. Aderholt. Thank you, Dr. Hamburg, for your testimony and, again, for being here this morning. Let's jump right on in to the budget request for fiscal year 2014. Your testimony says that you are asking for an additional $10 million, which is above the fiscal year 2012, for overseeing safety of products from China and that you will add 16 new inspectors in China. The question is, is that the same $10 million that was provided in the current CR for those activities? Dr. Hamburg. Yes. And I apologize for the confusion with the budget. This process has been a complex one this year with the work on developing fiscal year 2014 going forward, as there was uncertainty about funding levels for fiscal year 2013. But we are asking for a continuation of that $10 million to continue our efforts to oversee food and drug safety in China, imports from China. So we are asking for a continuation of the base that was now established with an addition of $10 million in the fiscal year 2013 budget, not an additional $10 million on top of that. Mr. Aderholt. There is $3.5 million in the request, again, above the fiscal year 2012 for medical countermeasures. Dr. Hamburg. Uh-huh. Mr. Aderholt. Did the committee already provide this funding as part of fiscal year 2013? Dr. Hamburg. Again, that is a continuation of the base. We do need that additional $3.5 million. We needed that $3.5 million in fiscal year 2013 to really round out the program that we need to implement this important area, to advance medical countermeasures availability for the American public. We need to continue that money in the base in fiscal year 2014. Mr. Aderholt. Okay. FSMA According to your testimony, FDA is seeking an additional $43 million to carry out responsibilities under the Food Safety Modernization Act, which you referred to in your opening comments. The fiscal year 2013 CR provided FDA with an additional $40 million for food safety. Does this $40 million request replace the one-time $40 million for food safety that was provided in the current CR? Dr. Hamburg. Well, I think in fiscal year 2013 the addition of $40 million is vitally important. We want to continue that in the base. And if that would be to occur, that there would be $40 million and we could get an additional $3 million to make $43 million in fiscal year 2014, that would be terrific. I should note that the $40 million in fiscal year 2013 was one-time, no-year money, and that is important in terms of our ability to use it effectively. Because we do need those resources, but because they came late in the budget cycle, we would have a hard time spending all of it within the fiscal year time frame. But we do need and are counting on those resources. WHITE OAK Mr. Aderholt. You had mentioned the White Oak facility, also, in your opening comments. FDA is seeking $17.7 million for the White Oak facility. Again, this committee provided these funds as part of the fiscal year 2013 CR, continuing resolution. Furthermore, fiscal year 2013 requests for these funds were described as a one-time request that would complete the $300 million investment at White Oak. Again, is this the same $17.7 million that was provided in fiscal year 2013? Because the reading of the budget justification looks like the money is for the same thing that was asked for and received in fiscal year 2013. Dr. Hamburg. Unlike the other two issues we just discussed, this would actually be a continuing need, an additional need in fiscal year 2014. There are further requirements for fully outfitting the laboratory, training the individuals, making sure that we have certification, adding critical components to make the laboratory work, such as the loading docks for delivery and pickup of materials, hazardous material handling services, et cetera. So those are actually additional needs on top of what was in the fiscal year 2013 funding. Mr. Aderholt. Okay. Yeah, let me just clarify. It looks like from the request that it is for the same thing, so we need some additional justification---- Dr. Hamburg. We would be very pleased---- Mr. Aderholt [continuing]. To provide that---- Dr. Hamburg [continuing]. To work with you and your staff to clarify. And, again, I apologize for the confusions that may have arisen in the budget process. [The information follows:] The White Oak funding request is a continuing need, maintaining the $17.7 million as a base in FY 2013 and providing additional funds in fiscal year '14. The FY 2013 enacted funds provides resources to make the Life Sciences complex operational. The FY 2014 request funds further requirements to fully outfit the laboratories, make sure that we have all necessary certifications, and add critical components to make the laboratories work such as the loading docks for delivery and pick up of materials. The fiscal year '14 requests are additional needs on top of what was in the fiscal year '13 funding. Sustaining the $17.7M provided in the fiscal year `13 appropriation will allow FDA to fund these additional FY 14 needs. Mr. Aderholt. Okay. Let me recognize Mr. Farr. USER FEES Mr. Farr. Thank you very much, Mr. Chairman. I want to follow up on the comment I made about the fee structure. You are collecting fees, but you are not allowed to spend them. What kind of a backlog do you have with not being able to spend those fees? Dr. Hamburg. Well, you know, of course, we are just beginning to implement the sequestration cuts, but it creates a very serious concern for us. We carefully negotiated with industry around a set of critical program goals and priority areas for work and performance measures to track our progress toward achieving those goals. And without the full funding that was evaluated as necessary to achieve those goals, we obviously will fall behind. And it will have implications for a number of important activities, in terms of medical product reviews, training and recruitment of critical staff---- Mr. Farr. What will that do to the private sector who is seeking the approvals? Dr. Hamburg. Well, I think it is troubling to them and to us that there were agreements made, including starting two critical new user fee programs in generics and biologics that will make a real difference to the American people, and those moneys are being collected from industry, but they are going into a bank, in essence, Treasury Department, I guess. And they can't be used to support our programs and activities; at the same time, they can't be used to offset the debt, as I understand it. So I think it is a troubling situation that compromises our ability to move forward in critical areas of mutual importance to industry and FDA and, of course, to all of our stakeholders that depend on our products. Mr. Farr. Mr. Chairman, I would hope that we might be able to look at that, just like we are looking at giving some flexibility to air traffic controllers, like we gave flexibility to the Department of Defense, plus a lot more money to the Department of Defense. And we ought to give the flexibility in these fee structures to the FDA to be used for the purposes for which they are collected. Let me ask you about the countermeasures that the chairman asked you about. It is 3 years since you began the countermeasure initiative, and Congress is always looking for ways to measure the success of these Federal programs. Has the FDA approved any drugs, biologics, or diagnostics to treat chemical, biological, radiological, or nuclear threats since establishing the MCMI? Dr. Hamburg. Yes, we actually have made enormous progress going forward in some key areas of activity. We have had a number of important new drug approvals: antibiotics for the treatment and prophylaxis of plague; a monoclonal antibody to treat inhalational anthrax and to prevent it under certain circumstances; a botulism antitoxin, which can make a real difference both in response to a potential biological threat and also naturally occurring disease; a number of important influenza diagnostics to help us address the potential of a pandemic threat as well as seasonal flu. We have also readied a number of products for use in an emergency. They are not fully approved but can be used as part of an emergency use authorization when there is a public health crisis, including a drug to treat smallpox and a smallpox vaccine. So these are very important advances. And with respect to the three new drug approvals that I mentioned, they have actually all included a pediatric indication, which has been a serious gap in some of the public health preparedness and medical countermeasure availability opportunities in the past. So it is an area of, I think, real progress that will make a difference to the American people. Mr. Farr. My question was going to be geared toward children, and you have answered that. I am pleased to see that we are moving forward with that, and hopefully we can strongly support you in that. One of the questions that comes up is the backlog on sunscreen. My brother-in-law, a surfer, very active guy who got melanoma and died in our house from melanoma, and we went through all the suffering that families go through. It just shocks me that we haven't done any new sunscreen approvals for a number of years, decades. I hear there are eight pending sunscreen applications, and none of them have yet been approved, none of them. So what is taking so long? Dr. Hamburg. Well, we have made some forward progress on issues of labeling and some other aspects of assessing safety and indications for an appropriate use of sunscreens. This issue that you describe is a priority for us, and, you know, we are trying to move forward with respect to both availability and safety of sunscreen products and their ingredients. With respect to the individual applications that you are mentioning, I actually am not aware of the particulars, but I am happy to follow up with you. Mr. Farr. Do you think something will be done this year? Dr. Hamburg. You know, I really don't want to speak to that since I don't know the specifics, but, as I said, I would like to follow up with you. But this is an area--sunscreens are regulated under the monograph framework. And the sunscreen monograph is, you know, one of the highest priorities. And a process is in place to try to move forward, I know, with respect to the overall regulation of sunscreens and to enable us to really apply the best possible science with respect to safety and ingredients and also issues around using data that has been collected in other settings, as well, including overseas. But we will follow up with your office. [The information follows:] [GRAPHIC] [TIFF OMITTED] T2639A.154 [GRAPHIC] [TIFF OMITTED] T2639A.155 Mr. Aderholt. Mr. Rogers. OXYCONTIN Mr. Rogers. Thank you, Mr. Chairman. Commissioner Hamburg, as we discussed last week on the phone and other times, I am thrilled by the FDA's decision to keep crushable generic OxyContin off the market. Young people, especially, were crushing those time-released pills, the 12- hour pill, crushing it, injecting it, and getting the immediate high from the 12-hour dose all at once. So I salute you for that. That will keep very dangerous drugs off of the street and out of our kids' hands. From a legal perspective, FDA determined that the reformulated OxyContin, the noncrushable one, did, in fact, possess abuse-deterrent characteristics and that the original crushable formulation was indeed removed for reasons of ``safety or effectiveness,'' end of quote. Dr. Hamburg. Uh-huh. Mr. Rogers. Now, that decision dealt with OxyContin, the Purdue Pharma product. How many other drug manufacturers currently have applications for abuse-deterrent formulations? Dr. Hamburg. You know, there is another product that is being looked at in that context, not in terms of a specific new application but in terms of whether or not it, in fact, meets the criteria for abuse deterrence. This is an important area, and one of our hopes is that we can better incentivize industry to work with us to develop models of abuse deterrence, to strengthen the existing approaches, such as the one used by Purdue in their product, but also develop new approaches, because we think this needs to be dynamic, as unfortunately abusers will no doubt figure out ways to overcome some of the abuse-deterrent strategies. So we put out a guidance, as I think you know, about how we think about criteria for meaningful abuse deterrence, and we are continuing to really try to work with industry to encourage more innovation in this area. We would like to see more product applications before us. Mr. Rogers. What standards will you apply in deciding whether these drugs will be approved and labeled for abuse deterrence? [The information follows:] As explained in the draft guidance entitled Evaluation and Labeling of Abuse-Deterrent Opioids (issued in January 2013), FDA generally will approve labeling describing a product's purportedly abuse-deterrent properties if, based on its review of all the available data, FDA concludes that those properties can be expected to, or actually do, result in a significant reduction in the product's abuse potential. If that standard is met, then the relevant data, together with a clear and accurate characterization of those data, should be included in product labeling. The draft guidance discusses the four categories of abuse potential studies FDA will examine to make its assessment, as well as examples of language that may be appropriate for inclusion in product labeling based on those data. FDA has received comments and will hold a public meeting on this draft guidance planned for September 30 to October 1, 2013. After that FDA will develop a final guidance. Dr. Hamburg. Well, it is outlined in the guidance. And I regret to say there are four criteria, as I recall, but I don't think I can reproduce them for you here. But the critical issue is whether, in fact, it can be demonstrated that they do what they say they do, that, in fact, they behave in ways that will significantly reduce the ability to crush and inhale or crush, melt, or otherwise liquify for injection these products. And we need to sort of see it scientifically in the laboratory context and also, you know, some evidence in terms of actual clinical experience. Mr. Rogers. Well, we want to be sure that the same standards are applied to generics and others as was applied to OxyContin. Dr. Hamburg. Absolutely. Mr. Rogers. And I am sure you are agreeable with that. Dr. Hamburg. I am. Can I just underscore, though, it is also very important that just because a company claims it is abuse-deterrent, it doesn't mean it is. So it is really in everybody's best interest that we try to have standards so that we can really achieve the goal. We don't want the standards to be so high that nobody can actually meet them. Mr. Rogers. Right. Dr. Hamburg. We want to incentivize industry to work on these kind of products. Mr. Rogers. Well, you are doing good work in this regard, because the Centers for Disease Control calls prescription drug abuse an epidemic. It is killing more people than car wrecks, especially young people. So your decisions so far, I think, will save lives. Let me ask you quickly about rescheduling hydrocodone combination drugs. In late January, the FDA Drug Safety and Risk Management Advisory Committee voted almost two to one to tighten restrictions for prescribing hydrocodone combination drugs. You don't have to follow their recommendation, but I am trying to figure out whether or not you will. I hope you do. Emergency room visits involving hydrocodone rose from 38,000 in 2004 to 115,000 in 2010. These drugs are often taken in combination with other drugs and/or alcohol, one of the most popular being what is called the holy trinity, a combination of hydrocodone with a sedative like Valium and a muscle relaxant. The current Schedule III classification for hydrocodone projects a false sense among some patients and doctors that Vicodin or Lortab are less potent or less habit-forming and, therefore, less dangerous than oxycodone painkillers, which are Schedule II. Prescriptions for Schedule II drugs can't be called in. You need to see a doctor to get a new prescription for each refill after 90 days, no automatic refill. As a result, while almost every opioid painkiller is considered a Schedule II drug and more carefully regulated, the most abused narcotic, hydrocodone, is missing from that list. So we have made pleas by letter to you. And I am wondering when you will decide this issue and where you think it is going. Dr. Hamburg. Well, it is an ongoing process, as you know. We did have an advisory committee, and, of course, you know, important information was discussed and they made a recommendation to us. We are looking at the information presented in that committee and other information that has come in to us from a range of stakeholders with, you know, frankly, differing perspectives on this issue, and trying to address the important issue of balance of access to critical medicines for legitimate medical needs and, you know, the potential, as you note, for abuse and misuse. We will be making a recommendation soon. I can't really speak to the direction that we are going or the specifics of timing. But I can assure you, Congressman Rogers, that when a decision is made, as I did with the other abuse-deterrent issue, I will reach out to you and let you know. Mr. Rogers. Well, I thank you. And I thank you for reaching out to me when you made the ruling on OxyContin. Finally, Mr. Chairman, on the matter of the labeling of the opioid narcotics, which up until now has said can be used for moderate to severe pain, I think it has misled doctors and patients that it is not as addictive a drug as it really is. And we have been pleading with FDA, I have for now 10 years, to restrict the labeling on OxyContin drugs and similar to just severe pain, which it was intended for, I think, in the first place. It is a great drug, a 12-hour release, for people who have horrible pain, terminally ill patients. But it has been thrown out there for toe aches and toothaches and everything else, misleading people that it is not as habit-forming and difficult to kick as it really is. Can you tell me when we might get some sort of indication of what may happen on changing the labeling to strike ``moderate''? Dr. Hamburg. Well, again, Congressman, as you know, we are in a process of consideration of these important issues and what is the appropriate management of acute and chronic pain with respect to this class of drugs. And we had a public meeting to hear presentations and get expert and public comment on these issues. We are reviewing that. We take the issue very, very seriously. We believe that FDA labeling and indications for use is an important component of what needs to be, of course, a multifaceted strategy to address this really critical and urgent public health problem. And we, you know, are actively engaged. I want to commend you for the leadership that you have taken on this issue and others, in terms of really making sure that adequate attention is paid and there is a sense of urgency. We do feel that and are working hard to really address it in a meaningful, scientifically based way. Mr. Rogers. Well, it shouldn't be a very difficult decision. I can't imagine why we would want to keep ``moderate pain'' labeling for such a dangerous drug that has proven a killer around the country. Congressman Frank Wolf and I, 10 years ago, came up to FDA and testified about this very issue of removing ``moderate'' on the label, which invites doctors and patients to use it for less than severe pain, and nothing happened. That was 10 years ago. So we have been sort of a lone wolf out there in the forest crying for help, but now we have some help. We are not alone anymore. A citizens' petition submitted to the FDA this summer, clinicians, researchers, health officials, all of them asking FDA to change the way opioid narcotics may be prescribed. They argue that, with the proper labels on prescription painkillers, physicians would be more aware of the safety concerns and effectiveness of certain opioids before unnecessarily prescribing highly addictive narcotics to patients for minor pain. So there is a growing consensus, I think, out there to do this and do it now. Dr. Hamburg. Well, we have heard you and your concerns, and we take them very seriously, and those of other stakeholders as well. As you know, we have taken steps with respect to some aspects of the labeling of opioids, the REMS that have been applied to the class of opioid drugs; voluntary requirements, as part of that, on physician education, which I think is absolutely key. We are hoping that there will be legislation that will actually include mandatory training as part of the DEA licensing for physicians who use these products because they are so powerful, both in effective treatment when indicated but also the potential for abuse. And we will be coming forward with a specific response to your question very soon. Mr. Rogers. Well, I thank you. Thank you for being here. Dr. Hamburg. Thank you. Mr. Rogers. I yield back. Mr. Aderholt. Thank you, Mr. Rogers. We have been joined by the ranking member of the full Appropriations Committee, Mrs. Lowey. And I will recognize you for any opening statement and also any questions that you may have at this time. Mrs. Lowey. Thank you, Mr. Chairman. And welcome, Commissioner Hamburg. We are indeed fortunate to have a person of your caliber in this position. Thank you very much. This week, there has been a lot of attention paid to the damaging effects of the sequester on the FAA and commercial air travel. While flight delays are an inconvenience and represent real economic losses to individuals, families, and businesses in New York and across the country, we can't ignore the real and dangerous effects of the sequester in other areas of our budget, especially when they have a profound consequence for public health. From frozen TV dinners to medical countermeasures, to addressing nuclear threats, to new drugs that treat major causes of death like cancer and heart disease, the American people rely on FDA and its expertise to review and approve products they use every single day. The repercussions of congressional inaction to replace the sequester are clear at the FDA. The agency will undertake 2,100 fewer inspections, which is at an 18 percent decline compared to last year. The implementation of the 2011 Food Safety Modernization Act will be further delayed, meaning we can continue to expect an estimated cost of $75 billion annually in lost productivity and medical expenses. And new drugs that reduce pain and sustain life will take longer to review and approve, robbing sick Americans of improved quality of life and more time with their loved ones. By cutting services and decreasing investments critical to our economic competitiveness, these across-the-board budget cuts are having a severe impact across all sectors of our economy. We must replace reckless, indiscriminate cuts with a renewed focus on jobs, economic growth, and a balanced fiscal package that creates long-term deficit reduction. And I just want to say, I look forward to a day soon when Chairman Rogers and I can work together in a bipartisan way and really address the serious issues as a result of sequestration, bring about regular order and do a budget that makes sense for the American people. We know that the discretionary budget is at its lowest level in the last 45 years as a percent of GDP. That is unacceptable. So I guess I made my message clear. Let me ask you a few questions. CELIAC DISEASE First of all, millions of Americans with celiac disease or gluten intolerance have been waiting for the FDA to finalize a standard for gluten-free labeling. Of course, it took me 5 years to get bipartisan support for just labels on food, which is food allergies, celiac disease, et cetera. GLUTEN-FREE LABELING In 2004, the Food Allergen Labeling and Consumer Protection Act that I authored became law. One of the provisions required the FDA to create a gluten-free labeling standard by August 2008. Nearly 5 years past the deadline and 9 years since the law was signed, I am still waiting for the administration to finalize the rule. I know that the rulemaking process is complicated. FDA must work with OMB and others. But when will a rule be finalized which will give those with celiac disease the peace of mind that the foods they purchase are truly gluten-free? By the way, no matter who I speak to, everyone seems to be going on a gluten-free diet. So it would be really helpful if we could be assured that what is declared gluten-free really is gluten-free. Dr. Hamburg. Well, you are right, this is a really important problem. And it does turn out, as we learn more about the nature of celiac disease and also broader nutritional concerns, that a gluten-free diet is benefiting more and more Americans. And it is critical that people have that information about the nature of their products and what is gluten-free. I had hoped I might have been able at a hearing at this moment in time to have been able to speak to the rule actually having been issued. It is in the final stages of administrative review, and I really do believe that you will see it soon. And as I promised Congressman Rogers on another matter, the first call I make will be to you. Mrs. Lowey. I hope it is soon. I think it is really very important. DRUG COMPOUNDING Another area that I have been particularly concerned with, as we all have, is drug compounding. The safety of products sold by compound pharmacies, particularly following last year's deadly meningitis outbreak, is a serious concern. In an effort to crack down on unsafe facilities, the FDA has recently conducted a number of inspections of these pharmacies. Could you share with us your findings? Dr. Hamburg. Yes. Well, we did recently undertake a fairly aggressive effort to do about 31 surveillance inspections of facilities that we considered potentially high-risk because they were making sterile injectable products. And we knew about them either because of past problems because of States telling us that they thought they should be on the high-risk list or, in some cases, what we learned, you know, from public and the media. And we also did another set of for-cause inspections in relation to reports that we were getting of actual concerns about products. I would have to say that those inspections were very concerning, because we did find real sterility concerns at many of the sites. I would underscore that these are facilities that, for the most part, aren't required to register with the FDA because they are compounding pharmacies, so they are not routinely inspected by us. But when we went in and looked at their standards for sterile processing, there were very real reasons for concern. We actually undertook a number of recalls of products that we thought represented a more imminent risk. And we certainly believe that it underscores the importance of a stronger, clearer regulatory and legal framework for oversight of these kinds of facilities. I think it is also really striking that, even in light of recent events, we had real trouble with a number of these inspections going in, having our authorities questioned. In two cases, we actually had to go to the courts to get administrative warrants so that we could do the full inspections and have access to the records that we needed to both assess what they were making and their business practices and really understand the risk. So we have indicated a very serious and urgent desire to work with Congress to create new, stronger, clearer legislation to provide the oversight of these facilities that I think the American people deserve and expect. Mrs. Lowey. Well, I certainly hope, Mr. Chairman, we can continue to work together to resolve this huge challenge. I have been told in talking with some people, since last year's deadly outbreak, there have been recalls, reports of additional serious infections, cases of reported blindness, loss of the eye associated with the use of repackaged Avastin for off-label treatment of wet age-related macular degeneration. So, as a clinician, I would assume you would agree that certain areas of the body, such as the eye, the brain, the spinal column, are least able to defend against infections and, thus, that any repackaged or compounded products which are injected into these areas, if they have compromised sterility, have a higher likelihood of causing injury or even death. So I would hope--and I will conclude, Mr. Chairman--that the FDA would consider prioritizing its oversight, while we are working on regulations, and enforcement activities to focus on those compounded or repackaged products that pose the most significant risk patients based on such risk factors. And would all patients benefit from a single quality standard relating to sterile injectables? Dr. Hamburg. We definitely believe that there needs to be clear, explicit standards for sterile practices that apply in a uniform way. In terms of FDA regulatory oversight, we think we can provide the greatest benefit in terms of where the risks are by really addressing, as you note, sterile injectable products. Those facilities that are making sterile injectables in advance of or without a prescription and selling across State lines, we think, represent the category that really presents the highest risk to the American public, though we think that, you know, clearly, any sterile product should be made in accordance with sterile procedures. Mrs. Lowey. Well, thank you, Mr. Chairman. It seems so obvious, it is shocking to me that this is a such a huge issue out there. And it is costing people their eyes, in some cases their life, and enormous expenses in trying to treat it. Thank you very much. And thank you, Mr. Chairman. Mr. Aderholt. Thank you, Ms. Lowey. Mr. Yoder. Mr. Yoder. Thank you, Mr. Chairman. Commissioner, thanks for being here today. BUDGET REDUCTIONS You know, as we have this discussion about how to properly handle the sequester and how to resolve the budget reductions that you are facing, you know, it is interesting to note that the Federal Government continues to grow at pretty significant rates. This year, the Federal Government will have more tax dollars from the American people than at any other time in history. Yet we are still running record deficits. And so I think we all know that, as you endeavor to try to figure out how to do more with less, and you are getting greater and greater requirements put upon you based upon implementation of the Obama healthcare bill, new laws passed by Congress--those are additional requirements that your agency didn't have some time ago--that that is what the private sector has had to deal with. And so, I know you get that. But just in context, while we have this debate and think about how we have to handle these reductions, for most of the American people, they have had to deal with much more than this. Folks have lost their jobs. They have had, you know, hours cut, salaries cut. I talked to a constituent yesterday who is having her hours cut because her employer doesn't want to have her have over 30 hours to qualify under the healthcare bill. And so, huge problems in the economy, some of which have been created by policies that have been pursued by Congress over the past few years that increase mandates on businesses, increase the cost of doing business. And I want to talk about a couple in particular of those, and then I have a few questions for you. One of the impacts on the economy have been billions of dollars in unfunded mandates, trillion in taxes, the healthcare law. We just raised taxes on January 1. And so, if those burdens weren't enough, we now have Federal food labeling mandates, which I know your agency is engaged in, on local grocers and convenience store owners. All of this is obviously, of course, bad for the economy, job creation, drives up the cost of doing business. FOOD LABELING And so, I know one of the mandates on the FDA was to try to help those requirements coming from the healthcare law have the most affordable way to be implemented. And so I guess I would ask, where are we on those food labeling requirements? Are we working hand-in-hand with our grocers and convenience store owners to ensure that these healthcare mandates that are required by law to come down the pike that you have to create rules for can be done in the most cost-beneficial manner as possible? And do we know what the impact is in terms of the outputs that these convenience store and grocery store owners are going to have to pay? Dr. Hamburg. Well, the healthcare reform act did include menu labeling, as you note, for chains of 20 or more and also for vending machines when there are 20 or more by the same owner. And we have been doing rulemaking on that, and it has been an extended process with proposed rules, you know, notice and comment. And we are now working through all of the comments that we have gotten in that process to put forward the final rule. One of the challenges of this, you know, to be frank, has been really defining what is a restaurant-like establishment. You know, what a restaurant is seems very straightforward, and I initially thought that implementing this was going to be, you know, one of the easier tasks before the FDA, but it has been actually enormously complicated. And, you know, some of the issues about convenience stores, box stores, movie theaters, different kinds of facilities that sell prepared food have all been, you know, part of the discussions and considerations. And we have attempted to look at both the public health impact and, of course, you know, the economic analyses required to look at the requirements for implementation, trying not to make an excessively burdensome rule but one that will have meaning and reflect the spirit of the legislation. So we will be, by the end of the calendar year, I think, putting out the final rule on menu labeling. Mr. Yoder. Do we know what the cost to comply is? I have seen some reports saying that it would be up to a billion dollars on grocers and convenience stores, and I have seen reports showing less. Does your agency have an idea of what this will cost these---- Dr. Hamburg. Well, the final---- Mr. Yoder [continuing]. Small-business owners? And how can the FDA help reduce those costs? Dr. Hamburg. Well, I think there have been various estimates out there, as people have sort of thought about different models for how the contours might be defined in terms of the broad array of restaurant-like establishments. You know, the final determinations have not been made in terms of which kinds of facilities will be in and which won't be. But we are looking at economic analyses as well as public health implications with respect to the overall consideration of the appropriate regulatory---- Mr. Yoder. And I have one question regarding the PDUFA user fees. When those fees are sequestered, do those fees go back to the paying entities, or are they allowed to be spent at a later date by the FDA? Is this a delay in expenditures, or is it actually a cut? And if it is a cut, then do the fees go back to the paying entities? Dr. Hamburg. You know, I think that is a question that is still being resolved at higher levels than I. The user fees are being subject to the same levels of cut in sequester as budget authority dollars. Those fees are still being collected from industry---- Mr. Yoder. Right. Dr. Hamburg [continuing]. But they are not going to support the FDA programs that were negotiated with industry as part of the collection of those user fees. Do you want to speak to---- Mr. Cochran. I guess the only other thing I would have to add is that FDA and the user fees, with regard to sequestration, follows guidance under OMB. And our understanding is that those dollars are held basically in FDA's account, and the only way that FDA would have the authority to spend them would be if Congress took action to effectively reappropriate them. Mr. Yoder. So, essentially, the money is still there. It is not necessarily a cut, it is a delay in spending; that FDA may get those dollars at a later if Congress gave them that permission. And I have to yield back. Dr. Hamburg. I don't know that for sure, but that would be---- Mr. Aderholt. Ms. DeLauro. Ms. DeLauro. Thank you very much, Mr. Chairman. And welcome, Commissioner. Thank you for the great job that you do with an amazing portfolio, which includes foods, drugs, devices, tobacco. It really is pretty extraordinary. And to that, I want to make a note about user fees, if I can quickly, so I can get to my questions. The FDA budget without user fees is $2.5 billion for 2014. Contrast, the request for NASA is $17 billion for 2014. Move back to 2013, you got $2.3 billion, NASA got $17 billion. It is 7.3 times larger than the FDA. Again, review the portfolio of this agency and what it does. We are not talking about hardware. We are not talking about--we are talking about life and death at the Food and Drug Administration. If we are serious, let us provide the FDA with the budget authority that it needs commensurate with the job that it does. And let's start, in fact, putting our money and our dollars where our mouths are. And I would rather have budget authority than user fees any day of the week and am willing to vote to give this agency the money it needs to get there. Before I start the questions, I am glad to hear that the FDA has moved forward on reclassifying tanning beds to their appropriate risk category, and long overdue. We will wait to see where we are. I hope to see, as the author of the--I would just say to my colleague, I authored the menu labeling rule, and it became part of the ACA, and it was to include movie theaters, chains-- we are talking about chains--chain grocery stores, and all similar retail establishments. I just want you to know--and this is about the movie industry, who claims that they are not in the food business. I take pictures when I go. This is chicken tenders, a chicken tender combo, hot dog and fries, cheese fries, a curly fry cone, mozzarella sticks, and funnel cake. We are not talking popcorn and soda any longer at movie theaters. We are talking about hot and cheesy and a kid's pack here, pretzel bites. Go to the movie theater, take pictures, and find out what business our movie theaters are in these days. So this is a key part of their marketing and their profit. And they ought to be required to label in the same way that the Restaurant Association agreed--and we worked very, very closely with the Restaurant Association to agree to put the calories up on the board. Dr. Hamburg, let me talk about--the question I really want to ask here is, the Trans-Pacific Partnership, that trade agreement, those negotiations are under way. I understand that some segments of the food industry are strongly advocating for a binding dispute resolution. What are your perspectives for making the SPS provisions subject to binding dispute settlement? Dr. Hamburg. Well, as you know, these are ongoing discussions and involve very important issues. We are a partner across government in these discussions. Our role is obviously to make sure that important issues of public health and public safety are adequately addressed in the agreements that are ultimately reached. We do think that there is a very clear role for incorporating technical consultative cooperation as part of a dispute resolution mechanism. Our concern, of course, is that we want decisions about the safety of imported products, the appropriateness of bringing certain kinds of products in for the American people, that those questions are adjudicated with the right subject-matter experts based on the best possible science and knowledge about the public health and medical implications. And so I think the issue of, you know, whether it is a binding dispute mechanism is one that needs further discussion and exploration. Because we would never want to be in a position where critical decisions would be locked into that might not reflect the best possible science, the subject-matter expertise necessary to best serve the health of the American people. And, you know, one needs to really think through what are the unintended consequences of various approaches that could be undertaken. Ms. DeLauro. There is a danger, in my view, about the integrity of the standards that are imperative to consumers and confidence in our food safety. I will just say the substance, ranging from the inspection process to specific microbiological standards, our zero tolerance for some of the most dangerous pathogens, can be put in harm's way if we move in this direction. I will continue to follow this with you. And I am hopeful. And maybe at another point, I want to know about your seat at the table in those trade negotiations and the weight of your voice in that effort. Thank you, Mr. Chairman. Mr. Aderholt. Thank you. And let me just say, we are going to try to stay to the 5- minute rule as close as possible because votes are coming up. So, at this time, I would like to recognize Mr. Valadao. FOLIC ACID PETITION Mr. Valadao. Thank you, Mr. Chair, Commissioner. Hispanic women are 20 percent more likely to have a child with neural tube defect, a devastating birth defect that can be permanently disabling or deadly. Up to 70 percent of these defects can be prevented if women of childbearing age had adequate levels of folic acid, B vitamin, before and in early pregnancy. For over a decade, our Nation has mandated that folic acid be added to enriched cereal grain products. Unfortunately, this does not include corn masa flour, a staple of many Hispanic women's diets. I understand that a petition was filed with the FDA over a year ago that proposes to allow the addition of folic acid to corn masa flour in products such as corn tortillas and tacos. What is the status of FDA's review of this petition? And I would urge you to ensure an expedient and reasonable review of the petition and be mindful that neural tube defects continue to occur while the FDA deliberates. Dr. Hamburg. This is a very important public health issue, and I have, you know, been briefed on it and am aware of the citizens' petition. I am not up to speed on the timing of that review, and, if I may, I would like to get back to you with the specific information on that. But it is certainly an issue that is on our radar screen and being worked on. And I will give you some more specific information, if I may. Mr. Valadao. All right. Thank you. Mr. Aderholt. Ms. Pingree. Ms. Pingree. Thank you, Mr. Chair. Thank you very much for being with us here today. It has been fascinating to hear the wide-ranging level of information that you have to cover. And I know there is a tremendous amount of responsibility that rests with your Agency. So thank you so much for your very hard work. I hear about the FDA from my constituents in a variety of ways. And I just want to take on one of the issues right now that you have talked a little bit about, and that is the Food Safety Modernization Act and the rule implementation that you are going through. I want to start by saying we all want our food to be safe, and every day we hear about a concern that people have about making sure our food is safe. I represent a lot of farmers, and I know I can say that I have never met a farmer who does not take very seriously their responsibility to produce good, safe food for consumers. I also want to commend my colleague, Rosa DeLauro. I know she worked so carefully to produce a bill that produced and ensured food safety for consumers. So I know that she also, from the consumer side, has been working extremely hard, as so many other Members of Congress have. During the debate on the Food Safety Modernization Act, Congress had a healthy discussion about one-size-fits-all regulations and how best to assess where risk actually comes from. I was encouraged the other day in the Senate hearings when Senator Tester was successful in reminding everyone that he had included a provision in the final food safety bill that works toward making regulations more workable for small and midsize farms involved in low-risk supply chains. And while I am encouraged that that is in there, I remain very concerned about the impact of the final rules on diversified small food producers. Unfortunately, for my first 4 years in Congress, I have heard almost nothing from the farmers in my district but fear, frustration, confusion about how the food safety rules are going to be implemented. They want to know how the rules will impact them and how they will fit into the system. They are very concerned about the cost and administrative burden that it will put on them and whether or not they will be able to stay in business. I have often talked frequently in front of this committee about the growing role of local foods and agriculture and how people are very interested in buying food from small retail outlets, from local foods, from CSAs, farmers markets. So I just want to make sure--and I know you have a lot of work left to do, and this is kind of long, but it is a deep concern of mine. I really want to make sure that you are looking at diversified operations, that you have those farmers in mind as you work to improve the proposed rule, and that you are scaling the regulation to the size of the farm and the amount of risk. The fact that different supply chains pose different levels of risk in our food supply must be part of the guiding principle that the FDA works with. I don't think that we want something that looks like a repeat of what happened with HACCP in the meat-processing rule a long time ago, which had the unintended consequence of shutting down hundreds of small meat processors, because they could no longer afford to do business. And it, in my opinion, hasn't provided the consumer with necessarily all safe or all perfect food. Some of the FDA estimates have said that the cost to comply with this proposed produce rule for farms with less than $250,000 of annual revenue will face over $22,000 in compliance costs. For many farmers who are just getting a start or are starting to grow or small farmers in my district, that is their profit for the year. So I hope you are looking carefully at how these rules will be imposed, really understanding some of the aggregation, food hubs, things that the Department of Agriculture on the one hand is promoting and we are finding great success with, and making sure that, as you look through how these rules are implemented, that there isn't an onerous burden and, in fact, it makes our food safer, but doesn't cut out the small and medium-size farmer. PROPOSED RULES--FSMA Dr. Hamburg. Well, I could give you a very quick answer to a very important question, which is that we are very mindful, we take this very seriously. We have tried, as we were shaping the proposed rules, to really do a lot of outreach, meet with the diverse grower community and actually, you know, go on to many of these different kinds of farms to get a better understanding of their issues and concerns. Of course, the original Food Safety Modernization Act did have the Tester amendment that excluded certain size farms and with limited distribution areas altogether. But as we think about the rules going forward and, of course, as we get feedback on the proposed rules that are out there for comment, you know, we are very much recognizing this set of issues. I think no matter who is growing and producing the food, you know, at the end of the day, everybody wants safe food. But we do need to recognize that the approaches need to be tailored to unique and differing needs, including both some of the approaches and also the phase-in to enable and support farmers who are trying to make a living and trying to produce safe, high-quality food. Ms. Pingree. Well, thank you very much. I am out of time, but I just want to say I am looking forward to working closely with the FDA. This is, as I said, an issue that I have heard probably as much about as anything else since I have been in Congress from the farmers and food processors in my area. And I hope we can continue to have a conversation about this. Thank you. Thanks, Mr. Chair. Mr. Aderholt. Mr. Fortenberry. Mr. Fortenberry. Thank you, Mr. Chairman. Thank you, Dr. Hamburg, for appearing today. Is our imported food safe? IMPORTED FOOD SAFETY Dr. Hamburg. You know, we are very fortunate in this country to have one of the safest food supplies in the world, but as the world has become more globalized, the volume of imported food has increased dramatically, and many of the foods that are being imported into this country are coming from places with much less sophisticated regulatory oversight and are commodities that are vulnerable intrinsically. And, you know, I did see a survey recently that showed that 61 percent of the American people are very concerned about the safety of imported food, and it is a concern that I share. And we are really making aggressive efforts at the FDA to respond to the growing volume of food safety imports, doing it in a number of different ways. But we feel that we have to strengthen oversight of these products in order to assure that the food Americans get in the grocery store and in other settings is as safe as it can possibly be, whether it comes from an imported source or a domestic source. Mr. Fortenberry. This is an interesting article, in The New York Times last year, ``China's Corrupt Food Chain,'' talking about how there is a significant lack of business ethics as well as distrust among Chinese people of their own food supply. Now, I don't know what the percent of food that we import comes from China. On medical devices, another category, I think you have pointed out that 80 percent of it comes from either China or India. So I don't know how that correlates to food imports---- Dr. Hamburg. Right. Mr. Fortenberry [continuing]. But I assume it is a significant percentage. And then 80 percent of our seafood is coming from overseas. And, again, I don't know how that correlates to China. But the larger generality here is that, given the aggressive expansion of food imports, there is real reason to be concerned here. CHINA FOOD SAFETY Dr. Hamburg. Yes. And, you know, we are very focused on a set of critical products and our working relationships with critical regions of the world that are importing products to us. China is a major partner in our efforts to improve food safety. We now have---- Mr. Fortenberry. Well, could you unpack that statement? Explain what that means, precisely. Dr. Hamburg. It means that we do get a large volume of products, food and medical products, from China, including active pharmaceutical ingredients in drugs used here. It means that we do need to really have a robust regulatory framework to address concerns, both known, existing concerns and also ones that we can anticipate possibly in the future. We now have three offices in China--Beijing, Shanghai, and Guangzhou--to strengthen our ability to be on the ground working with both industry and regulators in China---- Mr. Fortenberry. What percent of the---- Dr. Hamburg [continuing]. Doing more inspections. We have asked---- Mr. Fortenberry. What percent do we inspect? Dr. Hamburg. The percentage of facilities overseas that we are able to actually inspect is not very large. I don't know what the number is. We are doing many more foreign inspections than we have ever done in the past, but we are not going to be able to inspect our way out of the realities of the modern world and the challenges that we face. We also have to put in place new systems that involve new cooperative arrangements with regulatory authorities, more sharing of information, sharing of the workload in terms of inspections. We need more sophisticated screening methodologies that are based on risk. And we need industry to work with us to put in place the kinds of supply chain protections that are---- Mr. Fortenberry. My time is running short. I am sorry to interrupt you. But does the American taxpayer subsidize the inspection of food imports? In other words, what is the mechanism here by which those are paid for? Dr. Hamburg. Our inspectional program, whether it is domestic or imported, comes out of our budget. We in this budget are asking for user fees to also help to support some of our important import oversight activities and inspection activities. But, yes, our activities, whether domestic or international, for food safety come from our available budget. Mr. Fortenberry. Thank you, Mr. Chairman. Thank you. Mr. Aderholt. Mr. Bishop. Mr. Bishop. Thank you very much, Mr. Chairman. And thank you very much, Dr. Hamburg, for being here with your team. ANTIBIOTICS LIVESTOCK I have some questions I would like to explore with regard to antibiotics and livestock and poultry. I have consistently tried to look out for industry as well as the consumer and try to balance when it comes to regulations. And my thoughts have always been that regulations should be based in sound science, that they should be subjected to a cost-benefit analysis, and they should make common sense. And I appreciate very much, and this committee does, the FDA's efforts to examine the sales data of antibiotics. But some are saying that the data that you are collecting is flawed because of two things: One is that the data includes antibiotics that may be used on non-livestock species, and also because the data includes tracking ionophores. IONOPHORES Given that the mode of action for ionophores is extremely different from that of antibiotics and that, to the best of my knowledge, the use of ionophores in livestock does not pose any risk to humans, why does the FDA still classify ionophores as antibiotics? And I am going to ask my second question since we are running short on time. The fact that you monitor antimicrobial resistance and you keep track of trends in both the grocery store and on the farm, we have heard that the NARM program is currently undergoing some changes. And so I would like for you, after you answer the first question, to share with us why the program is being changed, what changes you are proposing, and particularly what changes with regard to home farm monitoring. Dr. Hamburg. Well, you have asked a lot of questions embedded in one and on very important public health issues. The problem with antibiotic resistance for both humans and animals is a very serious one, and we need to protect our ability to have antibiotics that really work against important infections. The use of antibiotics in animal populations is certainly a contributor, a major contributor, to some of the resistance that we have seen evolve over the years. And, you know, we are making very concerted efforts both to really understand the nature and scope of the problem and to address it. Importantly, you know, we are taking actions, as I am sure you know, to really achieve judicious use of the antibiotics that we have in both animal and human populations, but, with respect to animal husbandry, to make sure that antibiotics are not inappropriately used for growth promotion but are used to treat infections---- Mr. Bishop. I appreciate that very much. Dr. Hamburg [continuing]. Under the guidance of veterinarians. We do feel that our NARM system is very important, but that leaves---- Mr. Bishop. Excuse me. Before you get to the NARM system, the part of ionophores, which are different from antibiotics and which, from my understanding, has not proven to contribute to any resistance in humans. Dr. Hamburg. You know, I think that I can give you the best possible answer if we get back to you as part of the record, because I am not directly familiar with the data on ionophores. Mr. Bishop. Okay. And make sure that when you do get back, that it is based in sound science. Dr. Hamburg. Well, I will do my best. That is a guiding principle. [The information follows:] FDA clasifies ionophores as ``antimicrobials'' because they are used to treat infections in animals caused by certain non-bacterial microorganisms called coccidia. Section 512(1)(3) of the Federal Food and Drug and Cosmetic Act requires sponsors of antimicrobial new animal drugs to submit to FDA on an annual basis a report specifying ``the amount of each antimicrobial active ingredient in the drug that is sold or distributed for use in food-producing animals.'' This section also requires FDA to publicly report annual summaries of this antimicrobial sales and distribution data, which includes ionophores. But with respect to NARMS, you know, we are looking at it. We put out an ANPRM to get input from the public and stakeholders about how we could, you know, really effect some enhancements to our data collection systems to better inform our decision-making and make sure that we have good, solid data. Mr. Bishop. Thank you for that answer. But I was struck to find out that it appears that FDA is categorizing as antibiotics ionophores, which are quite different and have a different way of working in terms of being mixed with the feed for our livestock and our poultry. And, of course, that, again, as a proposed regulation--and I understand that you are looking at the anti-resistance developments--could have a great impact on the meat industry and the poultry industry as they process and grow the food that we eat. And, of course, it has to be balanced, but when you regulate, make sure that it is based in sound science, that it is subjected to a cost-benefit analysis, and that it makes good common sense. Thank you. Mr. Aderholt. Mr. Nunnelee. Mr. Nunnelee. Thank you, Mr. Chairman. Dr. Hamburg, thank you for being here. USER FEES--PHARMACEUTICALS Mr. Yoder had asked questions about the user fees paid for approval and analysis of pharmaceuticals. I will summarize what I thought I heard the answer is, that the users are still paying those fees, but some of them are being set aside in some kind of expense account that is not being used to evaluate the drugs. Is that right? Dr. Hamburg. Yeah. I mean, let me be clear, this is not an FDA policy. This is a decision or a determination based on the way in which the user fee dollars are appropriated, that they are treated like budget authority dollars. In terms of the impact on FDA, you are absolutely right. The user fees are being collected from the industries that we negotiated for those fees with, but they are not available for us to use as we stand up the new user fee programs or as we implement the ongoing ones. Of course, we have access to some of the user fees, but the total dollars available is being cut at the same level as the budget authority with respect to sequester. Mr. Nunnelee. All right, so what effect on approving potentially lifesaving drugs is this expense account that is sitting over to the side having on the FDA? Dr. Hamburg. Well, you know, of course, we are going to try to do as much as we can with what we have to achieve the important goals of these user fee programs. However, the dollar amounts in the user fee agreements reflected a very careful calculation of what were the critical needs, what were the goals, what would it take to achieve them. And when those dollars are cut, it means that we aren't going to be able to fully achieve the goals and the performance targets that were set in conjunction with industry in the user fee process. So we are worried that it will slow our ability to put out important guidances, to review applications that come before us, to do a set of important new hires, to stand up new programs and expand others, to improve business processes, to make our regulatory pathways more effective and efficient, and, importantly, to continue to do some of the work to develop the new regulatory tools that will make our regulatory system, you know, really appropriate for the sophistication and complexity of the products that are coming before us. And the other thing is that we know that the system works better when we can work more closely with the companies, the sponsors of the products to identify what kinds of data are going to be needed, the kinds of studies that would be most important for them to do, and have ongoing communication. And this will certainly limit the staff and flexibility to engage in those activities. Mr. Nunnelee. You said this is not of FDA's making. And in response to Mr. Yoder's question, you said, this was made at a higher level than I. Who made the decision? Dr. Hamburg. Well, I might turn to my colleague from the Department of Health and Human Services, who is a budget expert, but I believe it---- Mr. Cochran. Yeah, so the implementation or the execution of the sequester government-wide is determined or led by the Office of Management and Budget. And so the counsel at OMB has determined what the appropriate application of that sequester would be for user fees in this fiscal year. Mr. Nunnelee. So a lawyer at the Office of Management and Budget made the decision that we are going to take money that has already been paid, set it aside, and not do anything with it. And your testimony is that it is slowing the approval of potentially lifesaving drugs. Dr. Hamburg. My testimony is that we are concerned that the user fees were negotiated and specified with respect to a set of program activities and what they would cost to achieve, and if we have cuts in the available dollars, it will likely have meaningful impacts. Mr. Cochran. If I could just add, I think OMB's view is that this isn't an elective decision. This is their interpretation of the statute as it stands. Mr. Nunnelee. All right. Thank you, Mr. Chair. Mr. Aderholt. Okay. We are approaching a vote, and in consideration of--we have a series of votes. We will be on the floor for quite some time, so I don't anticipate that we could get back before 30 to 40 minutes. So we are going to wrap up. Several of us do have questions that we want to submit for the record, but we would ask, considering that we are going ahead and adjourning early, so that you are not left out here, and so that we can consolidate our schedules as well, that we could get expedited answers to these questions that will be for the record? Mr. Aderholt. But I think Ms. DeLauro has another question before we adjourn. Ms. DeLauro. Thank you very much, Mr. Chairman. I appreciate your indulgence. Just for the record, because my colleague, Mrs. Lowey, dealt with the compounded drugs and medical products, I would just very much like to have a--get back to me, you know, directly to my office about the authorities that you need, the specific authorities that you need in order to be able to address this issue. And I would ask you to take a look at the safe legislation that has been introduced in this area to tell us whether or not it helps to meet your concerns in how we can really mitigate against what is happening there. Food safety. The CDC is investigating an outbreak of salmonella, 18 States. That is associated with imported cucumbers. It takes up to 3 years to fully train a food safety inspector. FDA is not going to meet the target for foreign inspections this year or next, with only 1,200 planned inspections. 2016, FDA is supposed to inspect 19,000 foreign facilities. Tell us, if you are to meet FSMA's requirements for domestic and foreign inspections, will the FDA need more inspectors? If it does, when do they need to be hired? What does this budget do to meet the requirement? [The information follows:] [GRAPHIC] [TIFF OMITTED] T2639A.156 And then what I would like--again, I would like you to submit--I want you to answer those questions, but I would like you to submit for the record, also directly to my office, a detailed breakdown of your food inspection personnel, noting the number of personnel for domestic inspections and the number for international inspection. Thank you. [The information follows:] To respond to your question, we are providing the following document which details the breakdown of FDA foods inspection personnel. Please note, these numbers are the Full-Time Equivalent hours only for the inspections. This does not include support FTE, or FTE related to other Foods activities such as investigations, domestic or import sample collections or analysis, field exams/tests, import field exams or other operations. This also does not include inspections conducted through state contracts or partnerships. FDA FOODS INSPECTION PERSONNEL ---------------------------------------------------------------------------------------------------------------- FY2012 FY2012 FY2013 FY2014 Food Inspection Personnel * Estimate Actuals Estimate Estimate ---------------------------------------------------------------------------------------------------------------- Domestic.................................................... 331 323 348 348 Foreign..................................................... 44 56 44 44 --------------------------------------------------- Total................................................... 375 379 392 392 ---------------------------------------------------------------------------------------------------------------- Dr. Hamburg. Okay. Well, just a quick answer to your question, and then we will get back to you with more detail. But I do want to underscore that, actually, last year, we did meet our FSMA target for--in fact, exceeded it, I believe, for foreign inspections. But, of course, the numbers, as you know, in the legislation ramp up very quickly. Ms. DeLauro. 19,000 for 2016. Dr. Hamburg. And I do think that, you know, as we think about the real world that we live in and what is going to be required, we need to think about not just the role of inspections but other important activities as part of our overall program, many of which are reflected in new authorities in the Food Safety Modernization Act in terms of information- sharing, strengthening regulatory capacity in other countries, doing training, technical assistance. The Foreign Supplier Verification Program and third-party audit is going to be very, very important, as well, to our overall program that will address food safety. And, of course, the new rules, the produce safety and the preventive controls will apply whether you are a domestic or a foreign manufacturer or grower. So I think there are a number of things beyond inspections alone that will help to strengthen the security of the supply chain in our food imports. Ms. DeLauro. I would only add, Commissioner, that, in fact, if there is going to be a Trans-Pacific Partnership agreement, that the influx of imported seafood from Vietnam, from Thailand and Malaysia will be extraordinary. As my colleague, Mr. Fortenberry, pointed out, 80 percent of our seafood now comes-- it is imported. And we know, we know now, the rate of contamination and the import alerts that have occurred. That will make your job harder. We need to know on this committee what is required to ensure the public health of this country domestically, internationally, and how overwhelmed your agency may be if this committee doesn't do something about the resources that it supplies to you. Thank you very, very much, Mr. Chairman. Mr. Aderholt. Thank you, Ms. DeLauro. Again, this wraps up our last hearing for the budget for fiscal year 2014. I want to thank all the staff on both sides of the aisle for their work during this hearing process. And, again, we thank you for being here and look forward to---- Dr. Hamburg. Thank you. Mr. Aderholt [continuing]. Working with you as we proceed on with the fiscal year 2014 budget. Thank you. Dr. Hamburg. Thank you. [GRAPHIC] [TIFF OMITTED] T2639A.157 [GRAPHIC] [TIFF OMITTED] T2639A.158 [GRAPHIC] [TIFF OMITTED] T2639A.159 [GRAPHIC] [TIFF OMITTED] T2639A.160 [GRAPHIC] [TIFF OMITTED] T2639A.161 [GRAPHIC] [TIFF OMITTED] T2639A.162 [GRAPHIC] [TIFF OMITTED] T2639A.163 [GRAPHIC] [TIFF OMITTED] T2639A.164 [GRAPHIC] [TIFF OMITTED] T2639A.165 [GRAPHIC] [TIFF OMITTED] T2639A.166 [GRAPHIC] [TIFF OMITTED] T2639A.167 [GRAPHIC] [TIFF OMITTED] T2639A.168 [GRAPHIC] [TIFF OMITTED] T2639A.169 [GRAPHIC] [TIFF OMITTED] T2639A.170 [GRAPHIC] [TIFF OMITTED] T2639A.171 [GRAPHIC] [TIFF OMITTED] T2639A.172 [GRAPHIC] [TIFF OMITTED] T2639A.173 [GRAPHIC] [TIFF OMITTED] T2639A.174 [GRAPHIC] [TIFF OMITTED] T2639A.175 [GRAPHIC] [TIFF OMITTED] T2639A.176 [GRAPHIC] [TIFF OMITTED] T2639A.177 [GRAPHIC] [TIFF OMITTED] T2639A.178 [GRAPHIC] [TIFF OMITTED] T2639A.179 [GRAPHIC] [TIFF OMITTED] T2639A.180 [GRAPHIC] [TIFF OMITTED] T2639A.181 [GRAPHIC] [TIFF OMITTED] T2639A.182 [GRAPHIC] [TIFF OMITTED] T2639A.183 [GRAPHIC] [TIFF OMITTED] T2639A.184 [GRAPHIC] [TIFF OMITTED] T2639A.185 [GRAPHIC] [TIFF OMITTED] T2639A.186 [GRAPHIC] [TIFF OMITTED] T2639A.187 [GRAPHIC] [TIFF OMITTED] T2639A.188 [GRAPHIC] [TIFF OMITTED] T2639A.189 [GRAPHIC] [TIFF OMITTED] T2639A.190 [GRAPHIC] [TIFF OMITTED] T2639A.191 [GRAPHIC] [TIFF OMITTED] T2639A.192 [GRAPHIC] [TIFF OMITTED] T2639A.193 [GRAPHIC] [TIFF OMITTED] T2639A.194 [GRAPHIC] [TIFF OMITTED] T2639A.195 [GRAPHIC] [TIFF OMITTED] T2639A.196 [GRAPHIC] [TIFF OMITTED] T2639A.197 [GRAPHIC] [TIFF OMITTED] T2639A.198 [GRAPHIC] [TIFF OMITTED] T2639A.199 [GRAPHIC] [TIFF OMITTED] T2639A.200 [GRAPHIC] [TIFF OMITTED] T2639A.201 [GRAPHIC] [TIFF OMITTED] T2639A.202 [GRAPHIC] [TIFF OMITTED] T2639A.203 [GRAPHIC] [TIFF OMITTED] T2639A.204 [GRAPHIC] [TIFF OMITTED] T2639A.205 [GRAPHIC] [TIFF OMITTED] T2639A.206 [GRAPHIC] [TIFF OMITTED] T2639A.207 [GRAPHIC] [TIFF OMITTED] T2639A.208 [GRAPHIC] [TIFF OMITTED] T2639A.209 [GRAPHIC] [TIFF OMITTED] T2639A.210 [GRAPHIC] [TIFF OMITTED] T2639A.211 [GRAPHIC] [TIFF OMITTED] T2639A.212 [GRAPHIC] [TIFF OMITTED] T2639A.213 [GRAPHIC] [TIFF OMITTED] T2639A.214 [GRAPHIC] [TIFF OMITTED] T2639A.215 [GRAPHIC] [TIFF OMITTED] T2639A.216 [GRAPHIC] [TIFF OMITTED] T2639A.217 [GRAPHIC] [TIFF OMITTED] T2639A.218 [GRAPHIC] [TIFF OMITTED] T2639A.219 [GRAPHIC] [TIFF OMITTED] T2639A.220 [GRAPHIC] [TIFF OMITTED] T2639A.221 [GRAPHIC] [TIFF OMITTED] T2639A.222 [GRAPHIC] [TIFF OMITTED] T2639A.223 [GRAPHIC] [TIFF OMITTED] T2639A.224 [GRAPHIC] [TIFF OMITTED] T2639A.225 [GRAPHIC] [TIFF OMITTED] T2639A.226 [GRAPHIC] [TIFF OMITTED] T2639A.227 [GRAPHIC] [TIFF OMITTED] T2639A.228 [GRAPHIC] [TIFF OMITTED] T2639A.229 [GRAPHIC] [TIFF OMITTED] T2639A.230 [GRAPHIC] [TIFF OMITTED] T2639A.231 [GRAPHIC] [TIFF OMITTED] T2639A.232 [GRAPHIC] [TIFF OMITTED] T2639A.233 W I T N E S S E S ---------- Page Cochran, N. W.................................................... 177 Garcia, Juan..................................................... 1 Hamburg, M. A.................................................... 177 Heinen, Suzanne.................................................. 1 Scuse, Michael................................................... 1 Tyler, James..................................................... 177 Willis, Brandon.................................................. 1 Young, Michael................................................... 1